<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88058</article-id><article-id pub-id-type="doi">10.7554/eLife.88058</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88058.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-216208"><name><surname>Harris</surname><given-names>Noah J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-270208"><name><surname>Jenkins</surname><given-names>Meredith L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0685-5048</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312659"><name><surname>Nam</surname><given-names>Sung-Eun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312658"><name><surname>Rathinaswamy</surname><given-names>Manoj K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287469"><name><surname>Parson</surname><given-names>Matthew AH</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6270-559X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312660"><name><surname>Ranga-Prasad</surname><given-names>Harish</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312661"><name><surname>Dalwadi</surname><given-names>Udit</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312662"><name><surname>Moeller</surname><given-names>Brandon E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312663"><name><surname>Sheeky</surname><given-names>Eleanor</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1501-550X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-229414"><name><surname>Hansen</surname><given-names>Scott D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7005-6200</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-22353"><name><surname>Yip</surname><given-names>Calvin K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1779-9501</contrib-id><email>calvin.yip@ubc.ca</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-137057"><name><surname>Burke</surname><given-names>John E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7904-9859</contrib-id><email>jeburke@uvic.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04s5mat29</institution-id><institution>Department of Biochemistry and Microbiology, University of Victoria</institution></institution-wrap><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rmrcq20</institution-id><institution>Department of Biochemistry and Molecular Biology, The University of British Columbia</institution></institution-wrap><addr-line><named-content content-type="city">Vancouver</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0293rh119</institution-id><institution>Department of Chemistry and Biochemistry, Institute of Molecular Biology, University of Oregon</institution></institution-wrap><addr-line><named-content content-type="city">Eugene</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Andreotti</surname><given-names>Amy H</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rswrd78</institution-id><institution>Iowa State University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>07</month><year>2023</year></pub-date><volume>12</volume><elocation-id>RP88058</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-04-12"><day>12</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-04-12"><day>12</day><month>04</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.12.536585"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-23"><day>23</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88058.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-06-12"><day>12</day><month>06</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88058.2"/></event></pub-history><permissions><copyright-statement>© 2023, Harris, Jenkins et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Harris, Jenkins et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88058-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88058-figures-v1.pdf"/><abstract><p>PI3Kγ is a critical immune signaling enzyme activated downstream of diverse cell surface molecules, including Ras, PKCβ activated by the IgE receptor, and Gβγ subunits released from activated GPCRs. PI3Kγ can form two distinct complexes, with the p110γ catalytic subunit binding to either a p101 or p84 regulatory subunit, with these complexes being differentially activated by upstream stimuli. Here, using a combination of cryo electron microscopy, HDX-MS, and biochemical assays, we have identified novel roles of the helical domain of p110γ in regulating lipid kinase activity of distinct PI3Kγ complexes. We defined the molecular basis for how an allosteric inhibitory nanobody potently inhibits kinase activity through rigidifying the helical domain and regulatory motif of the kinase domain. The nanobody did not block either p110γ membrane recruitment or Ras/Gβγ binding, but instead decreased ATP turnover. We also identified that p110γ can be activated by dual PKCβ helical domain phosphorylation leading to partial unfolding of an N-terminal region of the helical domain. PKCβ phosphorylation is selective for p110γ-p84 compared to p110γ-p101, driven by differential dynamics of the helical domain of these different complexes. Nanobody binding prevented PKCβ-mediated phosphorylation. Overall, this work shows an unexpected allosteric regulatory role of the helical domain of p110γ that is distinct between p110γ-p84 and p110γ-p101 and reveals how this can be modulated by either phosphorylation or allosteric inhibitory binding partners. This opens possibilities of future allosteric inhibitor development for therapeutic intervention.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PIK3CG</kwd><kwd>p101</kwd><kwd>PIK3R5</kwd><kwd>PI3K</kwd><kwd>PI3Kγ</kwd><kwd>HDX-MS</kwd><kwd>nanobody</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>FDN-143228</award-id><principal-award-recipient><name><surname>Yip</surname><given-names>Calvin K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>PJT-168907</award-id><principal-award-recipient><name><surname>Yip</surname><given-names>Calvin K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><award-id>RGPIN-2018-03951</award-id><principal-award-recipient><name><surname>Yip</surname><given-names>Calvin K</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>MCB-2048060</award-id><principal-award-recipient><name><surname>Hansen</surname><given-names>Scott D</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>168998</award-id><principal-award-recipient><name><surname>Burke</surname><given-names>John E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000245</institution-id><institution>Michael Smith Health Research BC</institution></institution-wrap></funding-source><award-id>17686</award-id><principal-award-recipient><name><surname>Burke</surname><given-names>John E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Regulation of phosphoinositide 3 kinase (PI3Kγ) is essential in immune function, and stimuli that modulate the dynamics of the PI3Kγ helical domain can activate or inhibit kinase activity.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The class I phosphoinositide 3 kinases (PI3Ks) are master regulators of myriad functions through their generation of the lipid signaling molecule phosphatidylinositol 3,4,5-trisphosphate (PIP<sub>3</sub>) downstream of cell surface receptors (<xref ref-type="bibr" rid="bib11">Burke and Williams, 2015</xref>; <xref ref-type="bibr" rid="bib47">Rathinaswamy and Burke, 2020</xref>; <xref ref-type="bibr" rid="bib60">Vanhaesebroeck et al., 2021</xref>; <xref ref-type="bibr" rid="bib61">Vasan and Cantley, 2022</xref>). The class I PI3Ks can be further subdivided into the class IA and class IB subfamilies, with class IB PI3Ks being critical in immune signaling, and are composed of a single p110γ catalytic subunit that can bind to either a p101 or p84 regulatory subunit (<xref ref-type="bibr" rid="bib22">Hawkins and Stephens, 2015</xref>; <xref ref-type="bibr" rid="bib30">Lanahan et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Okkenhaug, 2013</xref>). The two PI3Kγ complexes (either p110γ-p84 or p110γ-p101) play essential and independent roles in both the adaptative and innate immune systems. Class IB PI3Kγ has shown promise as a therapeutic target, primarily as an immunomodulator of the tumor microenvironment leading to enhanced anti-tumor immune responses (<xref ref-type="bibr" rid="bib15">De Henau et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Kaneda et al., 2016b</xref>). Multiple isoform selective small molecule ATP competitive inhibitors of p110γ are in clinical trials for multiple forms of human cancers (<xref ref-type="bibr" rid="bib33">Li et al., 2021</xref>). However, all inhibitors currently developed toward p110γ act as ATP competitive inhibitors, showing equal potency against both p110γ-p84 and p110γ-p101 complexes.</p><p>Detailed experiments on the role of p110γ in mice show that knockout of both p101 and p84 leads to PIP<sub>3</sub> levels that are equivalent to knockout of p110γ, showing that all cellular PI3Kγ activities require the presence of either a p84 or p101 regulatory subunit (<xref ref-type="bibr" rid="bib53">Rynkiewicz et al., 2020</xref>). The two complexes are differentially activated by membrane localized receptors, including G-protein coupled receptors (<xref ref-type="bibr" rid="bib32">Li et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Stephens et al., 1997</xref>), Ras (<xref ref-type="bibr" rid="bib24">Jin et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Kurig et al., 2009</xref>), toll-like receptors (<xref ref-type="bibr" rid="bib36">Luo et al., 2018</xref>), and the IgE antigen receptor (<xref ref-type="bibr" rid="bib29">Laffargue et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>). This leads to the different complexes driving unique immune responses, with p110γ-p101 involved in chemotaxis in neutrophils (<xref ref-type="bibr" rid="bib5">Bohnacker et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Deladeriere et al., 2015</xref>), and p110γ-p84 involved in reactive oxide production. Differential activation of unique PI3Kγ complexes downstream of GPCRs and Ras is caused by the ability of p101 to directly bind to Gβγ subunits downstream of activated GPCRs, with this being lost in p84, making p110γ-p84 activation by Gβγ dependent on Ras-mediated membrane recruitment (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>; <xref ref-type="bibr" rid="bib28">Kurig et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Rynkiewicz et al., 2020</xref>). Activation of PI3Kγ downstream of the IgE antigen receptor is driven by calcium-mediated activation of protein kinase C, leading to the selective phosphorylation and activation of p110γ at S582 (<xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>), with this putatively only occurring in p110γ-p84 and not in p110γ-p101. The full molecular mechanisms underlying how phosphorylation of p110γ is selective for different p84 or p101 complexes, and how it activates lipid kinase activity are poorly understood.</p><p>Extensive biophysical approaches including cryo electron microscopy (cryo-EM), X-ray crystallography, and hydrogen-deuterium exchange mass spectrometry (HDX-MS) have provided extensive insight into the molecular underpinnings of how p110γ associates with both p101 and p84, how they are differentially activated by Ras and GPCR signals, and how they can be activated on lipid membranes (<xref ref-type="bibr" rid="bib42">Pacold et al., 2000</xref>; <xref ref-type="bibr" rid="bib62">Walker et al., 1999</xref>; <xref ref-type="bibr" rid="bib48">Rathinaswamy et al., 2021a</xref>; <xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>; <xref ref-type="bibr" rid="bib20">Gangadhara et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Vadas et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>). The p110γ catalytic subunit is composed of an adaptor binding domain (ABD), a Ras binding domain (RBD), a C2 domain, a helical domain, and a bi-lobal kinase domain (<xref ref-type="bibr" rid="bib48">Rathinaswamy et al., 2021a</xref>; <xref ref-type="bibr" rid="bib62">Walker et al., 1999</xref>). A set of helices positioned C-terminal to the activation loop in the kinase domain play a critical role in regulating activity, with this region referred to as the regulatory motif (<xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>). The p110γ isoform is unique in that it is inhibited in the absence of a regulatory subunit, with this driven by an autoinhibitory conformation of the regulatory motif, that is proposed to require membrane association to disrupt (<xref ref-type="bibr" rid="bib20">Gangadhara et al., 2019</xref>). The regulatory motif is a common site of activating mutations in the other class I PI3K isoforms (<xref ref-type="bibr" rid="bib23">Jenkins et al., 2023</xref>), with p110γ having rare activating oncogenic mutants in this region (<xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>). The p110γ subunit interacts with either p84 or p101 at an interface composed of the C2 domain, and the linkers between the RBD-C2 and C2-helical domains (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>). The p110γ-p84 complex forms a more dynamic complex compared to p110γ-p101 (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>; <xref ref-type="bibr" rid="bib55">Shymanets et al., 2013</xref>), however, no clear unique regulatory role of this difference in dynamics has been identified.</p><p>The fundamental roles of p110γ in inflammatory processes have made it a therapeutic target in many pathological conditions, including asthma (<xref ref-type="bibr" rid="bib13">Campa et al., 2018</xref>), arthritis (<xref ref-type="bibr" rid="bib14">Camps et al., 2005</xref>), obesity (<xref ref-type="bibr" rid="bib3">Becattini et al., 2011</xref>; <xref ref-type="bibr" rid="bib7">Breasson et al., 2017</xref>), and cancer (<xref ref-type="bibr" rid="bib15">De Henau et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Kaneda et al., 2016b</xref>; <xref ref-type="bibr" rid="bib26">Kaneda et al., 2016a</xref>). There are significant side effects from non-isoform selective PI3Kγ inhibitors (<xref ref-type="bibr" rid="bib6">Bohnacker et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Vanhaesebroeck et al., 2021</xref>), which has driven the development of highly p110γ selective small molecule inhibitors (<xref ref-type="bibr" rid="bib4">Bell et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Evans et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Gangadhara et al., 2019</xref>). However, all p110γ inhibitors will target both p110γ-p101 and p110γ-p84, so there is a potential for the development of allosteric inhibitors outside of the ATP binding site. Initial promise has been reported for the development of class IA p110α oncogene-specific allosteric inhibitors. However, further investigation of the molecular mechanisms underlying p110γ regulation will be required for the discovery of regions that can be targeted for allosteric inhibitor development.</p><p>Here, we report critical roles of the helical domain of p110γ in both activation and inhibition of lipid kinase activity. We characterized an allosteric inhibitory nanobody (NB7) that potently inhibits p110γ activity. Cryo-EM was used to define the inhibitory interface, which is composed of the helical domain, the ABD-RBD linker, and the regulatory motif of the kinase domain of p110γ. The region that the nanobody binds to is in close spatial proximity to a previously identified PKCβ phosphorylation site (S582) in the helical domain, and oncogenic activating mutants in the regulatory motif. We fully characterized the activity and dynamics of stoichiometrically PKCβ phosphorylated p110γ, leading to the discovery of a novel additional phosphorylation site (either S594 or S595). PKCβ phosphorylation was highly selective for p110γ and p110γ-p84, with limited phosphorylation of p110γ-p101. HDX-MS analysis showed that phosphorylation of p110γ leads to unfolding of the N-terminal region of the helical domain, and increased kinase activity. The presence of the inhibitory nanobody significantly blocks PKCβ phosphorylation, while phosphorylation of p110γ prevented binding to NB7. Overall, this work provides unique insight into the critical role of the helical domain in controlling p110γ activity, and how phosphorylation and binding partners can modify this regulation. It also reveals a unique binding site located at the interface of the helical and kinase domain that can be targeted for future allosteric inhibitor design.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Molecular mechanism of nanobody inhibition of p110γ</title><p>We previously identified multiple nanobodies that inhibited the activity of p110γ. One from this group (denoted NB7 throughout the manuscript) potently inhibited the membrane-mediated activation of p110γ-p84 by both Ras and Gβγ, with HDX-MS experiments mapping the NB7 binding interface to the RBD, helical and kinase domains (<xref ref-type="bibr" rid="bib49">Rathinaswamy et al., 2021b</xref>). We originally hypothesized that NB7 worked by sterically inhibiting Ras binding to the RBD of p110γ. To further explore the molecular mechanism of inhibition we purified all complexes of p110γ (p110γ apo, p110γ-p84, p110γ-p101) along with the NB7 nanobody. The SDS-PAGE of all proteins utilized in this study are shown in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p><p>To define the mechanism concerning how NB7 inhibits PI3Kγ activity we analyzed how this nanobody inhibited all class IB PI3Kγ complexes (p110γ, p110γ-p84, p110γ-p101) upon activation by lipidated Gβγ subunits. Intriguingly, we found that all three forms of p110γ were potently inhibited by NB7 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While the IC<sub>50</sub> measured for the three complexes was different, this is likely mainly due to the dramatic difference in protein required to measure lipid kinase activity in vitro (~300 nM for p110γ apo/p110γ-p84, and ~10 nM for p110γ-p101). This suggested that the mechanism of inhibition was not driven by a steric block of Ras association through the RBD, as previously proposed (<xref ref-type="bibr" rid="bib49">Rathinaswamy et al., 2021b</xref>). We examined the binding of this nanobody to all complexes using biolayer interferometry (BLI). The nanobody bound equivalently tightly to all complexes, with ~2 nM potency for p110γ, p110γ-p84, and p110γ-p101 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We also tested binding of the nanobody to all class IA PI3Ks, and there was no detectable binding to p110α, p110β, and p110δ (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The inhibitory nanobody NB7 binds tightly to all p110γ complexes and inhibits kinase activity, but does not prevent membrane binding.</title><p>(<bold>A</bold>) Cartoon schematic depicting nanobody inhibition of activation by lipidated Gβγ (1.5 µM final concentration) on 5% PIP<sub>2</sub> membrane (5% phosphatidylinositol 4,5-bisphosphate [PIP<sub>2</sub>], 95% phosphatidylserine [PS]) activation. Lipid kinase assays showed a potent inhibition of lipid kinase activity with increasing concentrations of NB7 (3–3000 nM) for the different complexes. Experiments are carried out in triplicate (n=3) with each replicate shown. The y-axis shows lipid kinase activity normalized for each complex activated by Gβγ in the absence of nanobody. Concentrations of each protein were selected to give a lipid kinase value in the detectable range of the ATPase Transcreener assay. The protein concentration of p110γ (300 nM), p110γ-p84 (330 nM), and p110γ-p101 (12 nM) was different due to intrinsic differences of each complex to be activated by lipidated Gβγ and is likely mainly dependent for the difference seen in NB7 response. (<bold>B</bold>) Association and dissociation curves for the dose response of His-NB7 binding to p110γ, p110γ-p84, and p110γ-p101 (50–1.9 nM) are shown. A cartoon schematic of biolayer interferometry (BLI) analysis of the binding of immobilized His-NB7 to p110γ is shown on the left. Dissociation constants (K<sub>D</sub>) were calculated based on a global fit to a 1:1 model for the top three concentrations and averaged with error shown. Error was calculated from the association and dissociation value (n=3) with standard deviation shown. Full details are present in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. (<bold>C</bold>) Association and dissociation curves for His-NB7 binding to p110γ, p110α-p85, p110β-p85, and p110δ-p85. Experiments were performed in duplicate with a final concentration of 50 nM of each class I phosphoinositide 3 kinase (PI3K) complex. (<bold>D</bold>) Effect of NB7 on PI3Kγ recruitment to supported lipid bilayers containing H-Ras (GTP) and farnesyl-G as measured by total internal reflection fluorescence microscopy (TIRF-M). DY647-p84/p110γ displays rapid equilibration kinetics and is insensitive to the addition of 500 nM nanobody (black arrow, 250 s) on supported lipid bilayers containing H-Ras (GTP) and farnesyl-G. (<bold>E</bold>) Kinetics of 50 nM DY647-p84/p110γ membrane recruitment appears indistinguishable in the absence and presence of nanobody. Prior to sample injection, DY647-p84/p110γ was incubated for 10 min with 500 nM nanobody. (<bold>F</bold>) Representative TIRF-M images showing the localization of 50 nM DY647-p84/p110γ visualized in the absence or presence of 500 nM nanobody (+NB7). Membrane composition for panels C–E: 93% DOPC, 5% DOPS, 2% MCC-PE, Ras (GTP) covalently attached to MCC-PE, and 200 nM farnesyl-G.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig1-v1.tif"/></fig><p>To further understand the mechanism by which this nanobody blocked lipid kinase activity we measured the bulk membrane recruitment dynamics of fluorescently labeled Dy647-p84-p110γ on supported lipid bilayers (SLBs) using total internal reflection fluorescence (TIRF) microscopy. We found that the nanobody had no effect on membrane recruitment of p110γ-p84 on bilayers containing membrane-tethered Ras (GTP) and Gβγ (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>). Membrane binding was not affected when the nanobody was spiked into samples containing membrane-associated Dy647-p84-p110γ (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Similarly, pre-incubation of Dy647-p84-p110γ with 500 nM NB7 did not perturb membrane association of the kinase when flowed over a supported membrane (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>We wanted to define the molecular mechanism of how nanobody NB7 was a potent allosteric inhibitor of lipid kinase activity. We purified the complex of nanobody NB7 bound to p110γ-p84 to homogeneity by gel filtration. Using this sample, we obtained a cryo-EM reconstruction of the complex of nanobody (NB7)-bound p110γ at 3.0 Å overall resolution from 149,603 particles (<xref ref-type="fig" rid="fig2">Figure 2A–D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and <xref ref-type="fig" rid="fig2s2">2</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The density map was of sufficient quality to perform automated and manual construction of the p110γ-NB7 complex, with unambiguous building of the interfacial contacts between NB7 and p110γ (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Nanobody binding did not induce any large-scale conformational changes of p110γ, as the structure of p110γ bound to NB7 was similar to the apo p110γ crystal structure or p110γ-p101 cryo-EM structure (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). The lowest local resolution was in the ABD, with increased B-factors of the ABD in the p110γ-NB7 structure compared to p110γ-p101 (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). This is consistent with the concept that ABD flexibility plays an important role in class I PI3K regulation (<xref ref-type="bibr" rid="bib34">Liu et al., 2022</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Structure of p110γ bound to inhibitory nanobody NB7.</title><p>(<bold>A</bold>) Domain schematics of p110γ with helical domain (blue), activation loop (orange), and regulatory motif (green) of p110γ annotated. (<bold>B</bold>) Cryo electron microscopy (cryo-EM) density of the p110γ-NB7 complex colored according to the schematic in (<bold>A</bold>). (<bold>C</bold>) Cartoon model of the structure of p110γ bound to NB7 colored according to (<bold>A</bold>). (<bold>D</bold>) Schematic depicting the key features of p110γ and the nanobody binding site, colored according to panel (<bold>A</bold>). (<bold>E</bold>) Domain schematic of NB7 complementarity determining regions (CDRs) and their sequences. (<bold>F</bold>) Zoom in on the binding interface of NB7, with the CDRs colored as in panel E, and the electron density of the CDRs contoured at 3σ (blue mesh).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>p110γ-NB7 complex cryo electron microscopy (cryo-EM) analysis workflow.</title><p>Cryo-EM processing workflow of p110γ-NB7 complex is shown in order of a representative micrographs, representative 2D classification and 3D reconstruction processing strategy. Bottom left shows gold-standard Fourier shell correlation (FSC) curve of final round on non-uniform homogenous refinement.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Density fit of p110γ-NB7 complex.</title><p>Model of p110γ (blue)/NB7 (red) complex in different orientations is shown fit within the cryo electron microscopy (cryo-EM) density map (green mesh).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Comparison of full-length p110γ bound to NB7 compared to p110γ-p101.</title><p>The structure of the p110γ-p101 complex (PDB: 7MEZ) compared to the NB7-p110γ complex is shown colored according to B-factor based on the legend.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig2-figsupp3-v1.tif"/></fig></fig-group><p>The interface between NB7 and p110γ was extensive, with ~1200 Å of buried surface area, with interactions of the ABD-RBD linker, N-terminus of the helical domain, and the regulatory motif at the turn between k8 and k9 (1022-1026aa). This location in the regulatory motif is where both activating oncogenic (R1021C) and inhibitory loss of function mutants have been identified (R1021P) (<xref ref-type="bibr" rid="bib58">Takeda et al., 2019</xref>), as well as a putative inhibitory phosphorylation site (T1024) (<xref ref-type="bibr" rid="bib44">Perino et al., 2011</xref>). The resolution was sufficient to unambiguously build the three complementarity determining region (CDR) loops of NB7 that mediate target selectivity (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>). The interface is primarily hydrophobic, with only 8 hydrogen bonds, and 1 electrostatic interaction among the 33 interfacial residues of NB7. A pocket formed between the helical domain and the ABD-RBD linker forms the majority of the interface, with extensive interactions with the long CDR3. The CDR1 loop packed up against the N-terminal section of the helical domain, with the CDR2 loop forming the interface with the regulatory motif. Previous study of oncogenic mutants in the regulatory motif of p110γ showed that increased dynamics mediated by these mutants increased kinase activity, putatively by breaking the autoinhibitory tryptophan lock in k12 of the regulatory motif (<xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>). Therefore, rigidifying the regulatory motif likely explains the molecular basis for how it prevents kinase activity. The nanobody interface is distinct from the predicted Gβγ interface (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>) and the experimentally resolved Ras interface (<xref ref-type="bibr" rid="bib42">Pacold et al., 2000</xref>), explaining why it can still be membrane recruited by these stimuli.</p><p>The interface of NB7 with p110γ is distant from both the putative membrane binding surface and the catalytic machinery of the kinase domain. To further understand how this nanobody could potently inhibit PI3Kγ activity we examined any other potential modulators of PI3Kγ activity localized in this region. There are two regulatory phosphorylation sites in the helical (<xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>) and kinase domain (<xref ref-type="bibr" rid="bib44">Perino et al., 2011</xref>) localized at the NB7 interface. This is intriguing as helical domain phosphorylation is activating, and kinase domain phosphorylation is inhibitory. This suggested that a critical role in the regulation of p110γ is the dynamics of this kinase-helical interface. To fully define the role of NB7 in altering the dynamics of the helical domain we needed to study other modulators of helical domain dynamics.</p></sec><sec id="s2-2"><title>p110γ activation by helical domain phosphorylation</title><p>To further understand the potential role of helical domain dynamics in controlling p110γ activity we examined the role of S582 helical domain phosphorylation by the protein kinase PKCβII (encoded by the gene <italic>PRKCB2</italic>, referred to as PKCβ for simplicity throughout the manuscript) (<xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>). S582 is located on the interior of the helical domain and would not be expected to be exposed when the N-terminal region of the helical domain is folded (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To understand this better at a molecular level, we purified a catalytic fragment of PKCβ and performed protein phosphorylation reactions on p110γ apo, p110γ-p84, and p110γ-p101. We identified a phosphorylated peptide containing S582, and surprisingly, we found an additional p110γ phosphorylation site at either S594/S595 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The modification at this site results in a single phosphorylation event, but due to CID MS/MS fragmentation we cannot determine which site is modified, and we will refer it as S594/S595 throughout the manuscript. The S594/S595 site is also located in the N-terminal region of the helical domain, and is even more buried than S582, and would not be expected to be exposed when this region is folded (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Dose-response curves of PKCβ treatment were carried out for p110γ (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), p110γ-p84 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), and p110γ-p101 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Both p110γ and p110γ-p84 showed similar dose-response curves for PKCβ treatment, with similar curves for S582 and S594/S595. The p110γ-p101 complex was only very weakly phosphorylated, with &lt;100-fold lower levels compared to p110γ and p110γ-p84 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). This is consistent with the helical domain in p110γ being more rigid when bound to p101, compared to either bound to p84 or p110γ alone.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PKCβ leads to dual phosphorylation of internal sites in the helical domain, with selectivity for apo p110γ and p110γ-p84 over p110γ-p101.</title><p>(<bold>A</bold>) Putative phosphorylation sites mapped on the structure of p110γ (PDB: 7MEZ) and cartoon schematic. The regions are colored based on domain schematics featured in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>B</bold>) Raw MS spectra of the unphosphorylated and phosphorylated peptide for a region spanning 579–592 (RYESLKHPKAYPKL) and 593–607 (FSSVKWGQQEIVAKT). The putative phosphorylation sites in the sequence are shown in red, with the m/z theoretical (m/z t) and m/z experimental (m/z t) shown below each sequence. (<bold>C–E</bold>) Extracted traces and ratios of the intensity of extracted ion traces of different phosphorylation site peptides (top to bottom: S594/S595 and S582) from (<bold>C</bold>) p110γ, (<bold>D</bold>) p110γ/p84, or (<bold>E</bold>) p110γ/p101 samples treated with increasing concentration of PKCβ according to the legend. The black traces in the ratio graphs are the intensity of the non-phosphorylated peptide, and the red traces in the ratio graphs are the intensity of the phosphorylated peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>MS/MS spectra of peptides spanning S582 and S594/S595 for both phosphorylated and unphosphorylated states.</title><p>The theoretical and experimental mass are annotated for all peptides.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To provide additional insight into the molecular mechanisms underlying p110γ phosphorylation we carried out HDX-MS experiments on p110γ and phosphorylated p110γ (90.8% phosphorylated S594/595, 92% phosphorylated S582) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The full data underlying the experiment is available in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>, and data processing information is in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. We have previously observed that the N-terminal region of the helical domain of apo p110γ (residues spanning 557-630aa) shows isotope profiles that are consistent with EX1 hydrogen-deutriuim (H/D) exchange kinetics (<xref ref-type="bibr" rid="bib49">Rathinaswamy et al., 2021b</xref>; <xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>; <xref ref-type="bibr" rid="bib59">Vadas et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>). This is indicative of cooperative unfolding of extended protein regions, with H/D exchange occurring faster than the refolding event. This region is where the PKCβ phosphorylation sites are located and may explain how the buried residues S582 and S594/S595 can be exposed to PKCβ. This is compatible with the observation that p110γ-p101 is protected from phosphorylation, as it does not show EX1 kinetics in this region, whereas both p110γ and p110γ-p84 do (<xref ref-type="bibr" rid="bib48">Rathinaswamy et al., 2021a</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Activating phosphorylation at the helical domain leads to opening of the regulatory motif.</title><p>(<bold>A</bold>) Hydrogen-deuterium exchange mass spectrometry (HDX-MS) comparing apo and phosphorylated p110γ. Significant differences in deuterium exchange are mapped on to the structure and cartoon of p110γ according to the legend (PDB: 7MEZ). (<bold>B</bold>) The graph of the #D difference in deuterium incorporation for p110γ, with each point representing a single peptide. Peptides colored in red are those that had a significant change in the mutants (greater than 0.4 Da and 5% difference at any time point, with a two tailed t-test p&lt;0.01). Error bars are SD (n=3). (<bold>C</bold>) Representative bimodal distribution (EX1 kinetics) observed in the helical domain peptides of p110γ. (<bold>D</bold>) Representative p110γ peptides displaying increases in exchange in the phosphorylated state are shown. For all panels, error bars show SD (n = 3). (<bold>E</bold>) Measurement of ATP to ADP conversion of phosphorylated and non-phosphorylated p110γ (1000 nM final concentration) ATPase activity in the absence (left) and presence of PIP<sub>2</sub> membranes (5% phosphatidylinositol 4,5-bisphosphate [PIP<sub>2</sub>], 95% phosphatidylserine [PS]) activation (right). Significance is indicated by **(&lt;0.001%) and ***(&lt;0.0001%).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig4-v1.tif"/></fig><p>When we compared phosphorylated p110γ (&gt;90.8% as measured by mass spectrometry at both sites) to unphosphorylated p110γ we observed extensive increases in dynamics in the C2, helical domain, and kinase domain (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>). The largest increases in exchange upon phosphorylation were located in the N-terminal region of the helical domain, with the peptides directly adjacent to the phosphorylation site showing almost complete deuterium incorporation at the earliest time points of exchange. This is indicative of significant disruption of the alpha helical secondary structure in this region. When we examined the exchange profiles in this region, they still underwent EX1 kinetics (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), however, phosphorylated p110γ was enriched in the more fully deuterated species. In addition to the regions in the helical domain, a portion of the regulatory motif of the kinase domain also showed increased deuterium exposure. This included the k9-k12 helices that surround the activation loop of p110γ. These increases in exchange were similar to those we had observed in a R1021C oncogenic activating mutant of <italic>PIK3CG</italic> (<xref ref-type="bibr" rid="bib50">Rathinaswamy et al., 2021c</xref>).</p><p>To further explore the potential role of phosphorylation in mediating p110γ activity, we examined the kinase activity of p110γ under two conditions: basal ATP turnover, and with PIP<sub>2</sub> containing lipid membranes. The experiments in the absence of PIP<sub>2</sub> measure turnover of ATP into ADP and phosphate and is a readout of basal catalytic competency. Experiments with PIP<sub>2</sub> measured ATP consumed in the generation of PIP<sub>3</sub>, as well as in non-productive ATP turnover. The p110γ enzyme in the absence of stimulators is very weakly active toward PIP<sub>2</sub> substrate with only ~2-fold increased ATP turnover compared to in the absence of membranes. This is consistent with very weak membrane recruitment of p110γ complexes in the absence of lipid activators (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>). PKCβ-mediated phosphorylation enhanced the ATPase activity of p110γ ~2-fold in both the absence and presence of membranes (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). This suggests that the effect of phosphorylation is to change the intrinsic catalytic efficiency of phosphorylated p110γ, with limited effect on membrane binding.</p></sec><sec id="s2-3"><title>Nanobody decreases p110γ phosphorylation</title><p>As NB7 bound at the interface of the helical and kinase domains that is exposed upon PKCβ phosphorylation of p110γ, we hypothesized that the nanobody would likely alter phosphorylation. We carried out PKCβ phosphorylation of p110γ, p110γ-p101, and p110γ bound to NB7. The presence of NB7 showed a significant decrease in p110γ phosphorylation at both sites (<xref ref-type="fig" rid="fig5">Figure 5A–B</xref>). We also wanted to determine whether p110γ phosphorylation reciprocally perturbed NB7 binding. BLI experiments showed that there was no detectable binding of NB7 to phosphorylated p110γ (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>), consistent with phosphorylation disrupting the N-terminal region of the p110γ helical domain. In addition, lipid kinase assays using phosphorylated p110γ showed no detectable difference in activity when measured in the absence and presence of nanobody (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), consistent with NB7 being unable to bind to phosphorylated p110γ.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Nanobody NB7 blocks PKCβ phosphorylation, and phosphorylation prevents nanobody binding.</title><p>(<bold>A</bold>) Extracted ion chromatograms for p110γ, p110γ-p101, and p110γ bound to NB7 are shown for the S594 or S595 phosphorylation site in p110γ. A bar graph showing the intensities of phosphorylated and non-phosphorylated p110γ peptide (593-607) for p110γ (black), p110γ with NB7 (red), and p110γ-p101 (purple) are shown to the right of the extracted ion chromatograms (n=3, right). In all experiments in panels A+B, PKCβ was present at 500 nM. Significance is indicated by ***(&lt;0.0001%). (<bold>B</bold>) Extracted ion chromatograms for p110γ, p110γ-p101, and p110γ bound to NB7 are shown for the S582 phosphorylation site in p110γ. A bar graph showing the intensities of phosphorylated and non-phosphorylated p110γ peptide (579-592) p110γ (black), p110γ with NB7 (red), and p110γ-p101 (purple) are shown to the right of the extracted ion chromatograms (n=3, right). Significance is indicated by *(&lt;0.01%) and ***(&lt;0.0001%). The putative phosphorylation site is shown in red in the sequence above the bar graphs for both panels A+B. (<bold>C</bold>) Cartoon schematic of biolayer interferometry (BLI) analysis of the binding of immobilized His-NB7 to phosphorylated and non-phosphorylated p110γ. (<bold>D</bold>) Association curves for phosphorylated and non-phosphorylated p110γ (25 nM) binding to His-NB7 are shown (n=3). (<bold>E</bold>) ATPase kinase activity assays comparing the activation/inhibition of phosphorylated and non-phosphorylated p110γ (1000 nM) with or without nanobody (3000 nM final) in the absence of PIP<sub>2</sub> membranes. Significance is indicated by *(&lt;0.05%) and NS (&gt;0.05%).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig5-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we find that the helical domain is a central regulator of the p110γ catalytic subunit of class IB PI3Kγ, with modulation of helical dynamics through binding partners or PTMs able to either increase or decrease lipid kinase activity. These results expand on previous work defining the helical domain as a central regulator of class IA PI3Ks, where the nSH2 domain of the p85 regulatory subunits makes inhibitory interactions that significantly inhibit lipid kinase activity of all class IA catalytic subunits (p110α, p110β, and p110δ) (<xref ref-type="bibr" rid="bib37">Mandelker et al., 2009</xref>; <xref ref-type="bibr" rid="bib39">Miled et al., 2007</xref>; <xref ref-type="bibr" rid="bib10">Burke and Williams, 2013</xref>; <xref ref-type="bibr" rid="bib12">Burke, 2018</xref>). This inhibitory interaction in class IA PI3Ks is disrupted in human cancers (helical hotspot mutations in <italic>PIK3CA</italic>) (<xref ref-type="bibr" rid="bib54">Samuels et al., 2004</xref>) and immune disorders (helical mutations in <italic>PIK3CD</italic> in APDS1) (<xref ref-type="bibr" rid="bib2">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Lucas et al., 2014</xref>). Class IB PI3Ks are uniquely compared to class IA PI3Ks, as they are not inhibited by p101 and p84 regulatory subunits, but instead potentiate GPCR activation. This lack of inhibition is due to the distinct binding interface of class IB PI3K regulatory subunits compared to class IA regulatory subunits, with only class IA regulatory subunits making direct inhibitory interactions with the kinase and helical domains of p110 catalytic subunits (<xref ref-type="bibr" rid="bib48">Rathinaswamy et al., 2021a</xref>). Here, we show that a unique surface at the interface of the helical and kinase domains of p110γ is a potential site for the development of novel allosteric inhibitors that modulate p110γ activity.</p><p>The previously identified inhibitory nanobody (NB7) (<xref ref-type="bibr" rid="bib49">Rathinaswamy et al., 2021b</xref>) bound with high affinity and inhibited all complexes of p110γ. The nanobody interface is distinct from how the nSH2 inhibits class IA PI3K activity, as its binding site is on the opposite face of the helical domain (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The mechanism of inhibition is also distinct, as the nSH2-helical interaction plays a critical role in preventing membrane recruitment of inhibited class I PI3Ks, with removal of this interface either through pYXXM motif binding or oncogenic mutations leading to increased membrane recruitment (<xref ref-type="bibr" rid="bib9">Burke et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Burke et al., 2011</xref>; <xref ref-type="bibr" rid="bib64">Zhang et al., 2011</xref>). Analysis of the nanobody binding site compared to the structure of HRas-p110γ or the HDX-MS supported Alphafold-multimer prediction of Gβγ-p110γ (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>) shows that nanobody binding does not sterically block complex formation (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). This is consistent with it not blocking membrane recruitment by Ras/Gβγ. The nanobody inhibited ATP turnover both in solution and on membranes, suggesting that it prevents formation of a catalytically competent conformation of p110γ, but still allows for membrane recruitment. Further development of small molecule allosteric binding partners in this allosteric pocket between the kinase and helical domain may reveal the specific molecular interactions in this pocket that mediate inhibition.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Comparison of nanobody binding site compared to p85 inhibition of class IA phosphoinositide 3 kinases (PI3Ks) and class IB activation sites.</title><p>(<bold>A</bold>) Comparison of the nanobody NB7 binding site in p110γ compared to the nSH2 inhibitory site in p110α (PDB: 3HHM) (<xref ref-type="bibr" rid="bib37">Mandelker et al., 2009</xref>). (<bold>B</bold>) Comparison of the nanobody NB7 binding site in p110γ compared to the X-ray structure of the Ras binding site (PDB: 1HE8) (<xref ref-type="bibr" rid="bib42">Pacold et al., 2000</xref>) and the Alphafold model of Gβγ bound to p110γ (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>). (<bold>C</bold>) Oncogenic mutations and post-translational modifications in spatial proximity to the nanobody binding site.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88058-fig6-v1.tif"/></fig><p>Oncogenic mutations are frequent in the class IA PI3K encoded by <italic>PIK3CA</italic>, with this being the second most frequently mutated gene in human cancer (<xref ref-type="bibr" rid="bib31">Lawrence et al., 2014</xref>). Mutations in p110γ encoded by <italic>PIK3CG</italic> in cancer are less frequent, however, they can still provide insight into regulatory mechanisms that control activity. Oncogenic mutations in the kinase domain (R1021C) and helical domain (E581K) are in close proximity to the nanobody binding site, and both would be expected to disrupt the stability of the helical domain or regulatory motif of the kinase domain (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). In addition to these mutations there are also multiple post-translational modifications that occur in this region, including inhibitory phosphorylation at T1024 (<xref ref-type="bibr" rid="bib44">Perino et al., 2011</xref>) and activating phosphorylation at S582 (<xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>). PKCβ is activated downstream of the IgE receptor in mast cells (<xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>), but the full details of how this activates PI3Kγ have been unclear. We identified an additional PKCβ phosphorylation site located in the helical domain (S594/S595) (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Both the S582 and S594/S595 sites are not surface accessible and would require a transient opening of the helical domain for kinase accessibility. HDX-MS analysis of the helical domain of p110γ has shown that it is more dynamic than other class I PI3K isoforms (<xref ref-type="bibr" rid="bib10">Burke and Williams, 2013</xref>; <xref ref-type="bibr" rid="bib63">Walser et al., 2013</xref>), with the presence of the p101 regulatory subunit dramatically decreasing helical domain dynamics (<xref ref-type="bibr" rid="bib59">Vadas et al., 2013</xref>). This putative mechanism of helical domain dynamics driving PKCβ phosphorylation is consistent with our observation that p101 subunits decreased p110γ phosphorylation &gt;100-fold. PKCβ phosphorylation of p110γ leads to increased dynamics in both the helical and kinase domains with increased kinase activity, although only weakly compared to full activation by either membrane localized Ras or Gβγ. This increase was observed with both membrane and soluble substrate, so likely is not driven by altered membrane recruitment.</p><p>Overall, our biophysical and biochemical analysis of modulators of helical domain dynamics reveal the critical role of this domain in regulating class IB PI3Kγ activity. This raises possibilities for development of small molecule modulators that may either increase or decrease helical domain dynamics, leading to either activation or inhibition. The high-resolution structure of an allosteric inhibitor nanobody provides initial insight into which pockets can specifically be targeted. Multiple ATP competitive p110γ selective inhibitors are in clinical trials for human cancers (<xref ref-type="bibr" rid="bib33">Li et al., 2021</xref>), with many having significant side effects. The identification of novel inhibitory strategies provides new opportunities for targeting p110γ dysregulation in human disease.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Plasmid generation</title><p>Plasmids encoding <italic>Homo sapiens</italic> p110γ (human), <italic>Mus musculus</italic> p84 (mouse), <italic>Sus scrofa</italic> p101 (porcine), and Gβγ were used as previously described (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>). The plasmids encoding the class IA PI3Ks were also used as previously described (<xref ref-type="bibr" rid="bib17">Dornan et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Siempelkamp et al., 2017</xref>). The pDONR223-PRKCB2 (PKCβII, uniprot identifier: P05771-2) was a gift from William Hahn &amp; David Root (Addgene plasmid #23746; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene">http://n2t.net/addgene</ext-link>: 23746; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_23746">Addgene_23746</ext-link>) (<xref ref-type="bibr" rid="bib25">Johannessen et al., 2010</xref>). The PKCβII construct contains an internal TEV site that cleaves the catalytic domains from the C1/C2 regulatory domains (TEV site inserted between residues 320 and 321 of PKCβ). This construct was subcloned into a pACEBAC Sf9 expression vector for Sf9 protein production. All constructs were cloned to include a 10× histidine tag, a 2× strep tag, and a tobacco etch virus protease cleavage site on the N-terminus. For p110γ and PKCβII this tag was included at the N-terminus, with this tag included at the N-terminus of either p84 or p101 for purification of p110γ-p101 and p110γ-p84. Full details of the plasmids are included in Appendix 1—key resources table.</p></sec><sec id="s4-2"><title>Virus generation and amplification</title><p>The plasmids encoding genes for insect cell expression were transformed into DH10MultiBac cells (MultiBac, Geneva Biotech) to generate bacmid containing the genes of interest. Successful generation was identified by blue-white colony screening and the bacmid was purified using a standard isopropanol-ethanol extraction method. Bacteria were grown overnight (16 hr) in 3–5 mL 2xYT (BioBasic #SD7019). Cells were spun down and the pellet was resuspended in 300 μL of 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 mg/mL RNase A. The pellet was lysed by the addition of 300 μL of 1% sodium dodecyl sulfate (SDS) (wt/vol), 200 mM NaOH, and the reaction was neutralized by addition of 400 μL of 3.0 M potassium acetate, pH 5.5. Following centrifugation at 21130 RCF and 4°C (Rotor #5424R), the supernatant was mixed with 800 μL isopropanol to precipitate bacmid DNA. Following centrifugation, the pelleted bacmid DNA was washed with 500 μL 70% ethanol three times. The pellet was then air dried for 1 min and re-suspended in 50 μL Buffer EB (10 mM Tris-Cl, pH 8.5; all buffers from QIAprep Spin Miniprep Kit, QIAGEN #27104). Purified bacmid was then transfected into Sf9 cells. Two mL of Sf9 cells at 0.6×10<sup>6</sup> cells/mL were aliquoted into a six-well plate and allowed to attach to form a confluent layer. Transfection reactions were prepared mixing 8–12 μg of bacmid DNA in 100 μL 1×PBS and 12 μg polyethyleneimine (Polyethyleneimine ‘Max’ MW 40.000, Polysciences #24765, USA) in 100 μL 1×PBS and the reaction was allowed to proceed for 20–30 min before addition to an Sf9 monolayer containing well. Transfections were allowed to proceed for 5–6 days before harvesting virus containing supernatant as a P1 viral stock.</p><p>Viral stocks were further amplified by adding P1 to Sf9 cells at ~2 × 10<sup>6</sup> cells/mL (2/100 volume ratio). This amplification was allowed to proceed for 4–5 days and resulted in a P2 stage viral stock that was used in final protein expression. Harvesting of P2 viral stocks was carried out by centrifuging cell suspensions in 50 mL Falcon tubes at 2281 RCF (Beckman GS-15). To the supernatant containing virus, 5–10% inactivated fetal bovine serum (FBS; VWR Canada #97068-085) was added and the stock was stored at 4°C.</p></sec><sec id="s4-3"><title>Expression and purification of PI3Kγ, PI3Kα/β/δ, and PKCβ constructs</title><p>PI3Kγ <italic>and PKCβ</italic> constructs were expressed in Sf9 insect cells using the baculovirus expression system. Following 55 hr after infection with P2 viral stocks, cells were harvested by centrifuging at 1680 RCF (Eppendorf Centrifuge 5810R) and the pellets were snap-frozen in liquid nitrogen. The complex was purified through a combination of nickel affinity, streptavidin affinity, and size-exclusion chromatography.</p><p>Frozen insect cell pellets were resuspended in lysis buffer (20 mM Tris pH 8.0, 100 mM NaCl, 10 mM imidazole pH 8.0, 5% glycerol [vol/vol], 2 mM ME), protease inhibitor (Protease Inhibitor Cocktail Set III, Sigma) and sonicated for 2 min (15 s on, 15 s off, level 4.0, Misonix sonicator 3000). Triton X was added to the lysate to a final concentration of 0.1% and clarified by spinning at 15,000 RCF at 4°C for 45 min (Beckman Coulter JA-20 rotor). The supernatant was loaded onto a 5 mL HisTrap FF crude column (GE Healthcare) equilibrated in NiNTA A buffer (20 mM Tris pH 8.0, 100 mM NaCl, 20 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM ME). The column was washed with high salt NiNTA A buffer (20 mM Tris pH 8.0, 1 M NaCl, 20 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM ME), NiNTA A buffer, 6% NiNTA B buffer (20 mM Tris pH 8.0, 100 mM NaCl, 250 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM ME) and the protein was eluted with 100% NiNTA B. The eluent was loaded onto a 5 mL StrepTrap HP column (GE Healthcare) equilibrated in gel filtration buffer (20 mM Tris pH 8.5, 100 mM NaCl, 50 mM ammonium sulfate and 0.5 mM tris(2-carboxyethyl) phosphine [TCEP]). To purify <italic>PI3Kα/β/δ</italic>, the purification protocol was performed as described above but instead the protein was eluted in PI3K<italic>α</italic> gel filtration buffer (20 mM HEPES 7.5, 150 mM NaCl, 0.5 mM TCEP). The column was washed with the corresponding gel filtration buffer and loaded with tobacco etch virus protease. After cleavage on the column overnight, the PI3K protein constructs were eluted in gel filtration buffer. The protein was concentrated in a 50,000 MWCO Amicon Concentrator (Millipore) to &lt;1 mL and injected onto a Superdex 200 10/300 GL Increase size-exclusion column (GE Healthcare) equilibrated in gel filtration buffer. After size exclusion, the protein was concentrated, aliquoted, frozen, and stored at –80°C. For PKCβ, the protein was eluted from the strep column in gel filtration buffer, and the eluate was then loaded on a 1 mL HisTrap FF column to remove his tagged LipTev. The flowthrough was collected, and the column was washed with 2 mL of gel filtration buffer. These fractions were pooled and concentrated and stored at –80°C.</p><p>To purify phosphorylated p110γ, the purification protocol as described above was performed but PKCβ was added to the strep column at a molar ratio of 1:3 (PKCβ:p110γ) along with LipTEV, 20 mM MgCl<sub>2</sub>, and 1 mM ATP and allowed to incubate on ice for 4 hr. The protein was eluted by adding 7 mL of gel filtration buffer and treated with a second dose of PKCβ (same ratio as above) and allowed to incubate on ice for another 3 hr. For non-phosphorylated p110γ, same protocol was followed with the exception in the addition of PKCβ. Both the proteins were concentrated in a 50,000 MWCO Amicon Concentrator (Millipore) to &lt;1 mL and injected onto a Superdex 200 10/300 GL Increase size-exclusion column (GE Healthcare) equilibrated in gel filtration buffer. The final phosphorylation level of the two sites was characterized by mass spectrometry, with these values being 92% and 90.8%, for S582 and S594/S595, respectively. After size exclusion, the protein was concentrated, aliquoted, frozen, and stored at –80°C.</p></sec><sec id="s4-4"><title>Expression and purification of lipidated G for kinase activity assays</title><p>Full-length, lipidated human <italic>Gβγ</italic> (Gβ1γ2) was expressed in Sf9 insect cells and purified as described previously. After 65 hr of expression, cells were harvested, and the pellets were frozen as described above. Pellets were resuspended in lysis buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM βME, protease inhibitor [Protease Inhibitor Cocktail Set III, Sigma]) and sonicated for 2 min (15 s on, 15 s off, level 4.0, Misonix sonicator 3000). The lysate was spun at 500 RCF (Eppendorf Centrifuge 5810R) to remove intact cells and the supernatant was centrifuged again at 25,000 RCF for 1 hr (Beckman Coulter JA-20 rotor). The pellet was resuspended in lysis buffer and sodium cholate was added to a final concentration of 1% and stirred at 4°C for 1 hr. The membrane extract was clarified by spinning at 10,000 RCF for 30 min (Beckman Coulter JA-20 rotor). The supernatant was diluted three times with NiNTA A buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM imidazole, 0.1% C12E10, 10 mM ME) and loaded onto a 5 mL HisTrap FF crude column (GE Healthcare) equilibrated in the same buffer. The column was washed with NiNTA A, 6% NiNTA B buffer (20 mM HEPES pH 7.7, 25 mM NaCl, 250 mM imidazole pH 8.0, 0.1% C12E10, 10 mM ME) and the protein was eluted with 100% NiNTA B. The eluent was loaded onto HiTrap Q HP anion exchange column equilibrated in Hep A buffer (20 mM Tris pH 8.0, 8 mM CHAPS, 2 mM dithiothreitol [DTT]). A gradient was started with Hep B buffer (20 mM Tris pH 8.0, 500 mM NaCl, 8 mM CHAPS, 2 mM DTT) and the protein was eluted in ~50% Hep B buffer. The eluent was concentrated in a 30,000 MWCO Amicon Concentrator (Millipore) to &lt;1 mL and injected onto a Superdex 75 10/300 GL size-exclusion column (GE Healthcare) equilibrated in Gel Filtration buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM CHAPS, 2 mM TCEP). Fractions containing protein were pooled, concentrated, aliquoted, frozen, and stored at –80°C.</p></sec><sec id="s4-5"><title>Expression and purification of nanobody</title><p>Nanobody NB7-PIK3CG with a C-terminal 6× His tag was expressed from a pMESy4 vector in the periplasm of WK6 <italic>E. coli</italic>. A 1 L culture was grown to OD600 of 0.7 in Terrific Broth containing 0.1% glucose and 2 mM MgCl<sub>2</sub> in the presence of 100 μg/mL ampicillin and was induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG). Cells were harvested the following day by centrifuging at 2500 RCF (Eppendorf Centrifuge 5810R) and the pellet was snap-frozen in liquid nitrogen. The frozen pellet was resuspended in 15 mL of TES buffer containing 200 mM Tris pH 8.0, 0.5 mM ethylenediaminetetraacetic acid (EDTA), and 500 mM sucrose and was mixed for 45 min at 4°C. To this mixture, 30 mL of TES buffer diluted four times in water was added and mixed for 45 min at 4°C to induce osmotic shock. The lysate was clarified by centrifuging at 14,000 rpm for 15 min (Beckman Coulter JA-20 rotor). Imidazole was added to the supernatant to final concentration of 10 mM loaded onto a 5 mL HisTrap FF crude column (GE Healthcare) equilibrated in NiNTA A buffer (20 mM Tris pH 8.0, 100 mM NaCl, 20 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM β-mercaptoethanol [ME]). The column was washed with high salt NiNTA A buffer (20 mM Tris pH 8.0, 1 M NaCl, 20 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM ME), followed by 100% NiNTA A buffer, then a 6% NiNTA B wash buffer (20 mM Tris pH 8.0, 100 mM NaCl, 250 mM imidazole pH 8.0, 5% [vol/vol] glycerol, 2 mM ME) and the protein was eluted with 100% NiNTA B. The eluent was concentrated in a 10,000 MWCO Amicon Concentrator (Millipore) to &lt;1 mL and injected onto a Superdex 75 10/300 GL Increase size-exclusion column (GE Healthcare) equilibrated in gel filtration buffer (20 mM Tris pH 8.5, 100 mM NaCl, 50 mM ammonium sulfate, and 0.5 mM TCEP). Following size exclusion, the protein was concentrated, frozen, and stored at –80°C.</p></sec><sec id="s4-6"><title>Lipid vesicle preparation for kinase activity assays</title><p>Lipid vesicles containing 5% brain phosphatidylinositol 4,5-bisphosphate (PIP2) and 95% brain phosphatidylserine (PS) were prepared by mixing the lipids solutions in organic solvent. The solvent was evaporated in a stream of argon following which the lipid film was desiccated in a vacuum for 45 min. The lipids were resuspended in lipid buffer (20 mM HEPES pH 7.0, 100 mM NaCl, and 10% glycerol) and the solution was vortexed for 5 min followed by sonication for 15 min. The vesicles were then subjected to 10 freeze thaw cycles and extruded 11 times through a 100 nm filter (T&amp;T Scientific: TT-002-0010). The extruded vesicles were sub-aliquoted and stored at –80°C. Final vesicle concentration was 2 mg/mL.</p></sec><sec id="s4-7"><title>Kinase assays</title><p>All kinase assays were done using Transcreener ADP2 Fluorescence Intensity (FI) assays (Bellbrook labs) which measures ADP production. All assays contained ATP at a final concentration of 100 μM, and those with membranes used vesicles containing 5% PIP<sub>2</sub> and 95% PS at a final concentration of 0.5 mg/mL.</p><p>For assays measuring the inhibition by nanobody, 4× kinase (final concentration: 330 nM for p110γ, 300 nM for p110γ/p84, and 12 nM for p110γ/p101) was mixed with varying 4× concentrations of nanobody (final concentration: 2 μM to 2.7 nM) or kinase buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.03% CHAPS, 2 mM TCEP, and 1 mM EGTA) and allowed to sit on ice for 15 min. Two μL of protein mix was mixed with 2 μL of lipid solution containing Gβγ (1 μM final concentration), ATP (100 μM), PIP<sub>2</sub> lipid vesicles (0.5 mg/ml final concentration), and lipid buffer (25 mM HEPES pH 7, 5% glycerol, and 100 mM NaCl) and incubated at 20°C for 60 min.</p><p>For assays comparing the difference in activation between phosphorylated and non-phosphorylated p110γ, 2× kinase (final concentrations: 1 μM) was mixed with 2× lipid solutions containing ATP (100 μM), and lipid buffer and either nanobody (3 μM final concentration), PIP<sub>2</sub> lipid vesicles (0.5 mg/mL final concentration), or both nanobody and lipid. The reaction was incubated at 20°C for 60 min.</p><p>After the 60 min incubation, all reactions were stopped with 4 μL of 2× stop and detect solution containing Stop and Detect buffer (20 mM HEPES,0.02% Brij-35, 40 mM EDTA pH 7.5), 8 nM ADP Alexa Fluor 594 Tracer and 93.7 μg/mL ADP2 Antibody IRDye QC-1, covered and incubated at 20°C for 1 hr before reading the fluorescence. The fluorescence intensity was measured using a SpectraMax M5 plate reader at excitation 590 nm and emission 620 nm. All data was normalized against the appropriate measurements obtained for 100 μM ATP and 100 μM ADP with no kinase. The percent ATP turnover was interpolated using a standard curve (0.1–100 μM ADP). Interpolated values were then used to calculate the specific activity of the enzyme.</p></sec><sec id="s4-8"><title>Biolayer interferometry</title><p>All BLI experiments were performed using the Octet K2 instrument (Fortebio Inc). For all experiments His-tagged nanobody (500 nM) was immobilized on an Anti-Penta-His biosensor for 600 s, and the sensor was dipped into varying concentrations of the protein complex being measured. A dose response was carried out for p110γ, p110γ-p84, and p110γ-p101 (50 nM – 1.9 nM), with association occurring for 600 s, followed by a 1200s dissociation in Octet Buffer (20 mM Tris pH 8.5, 100 mM NaCl, 50 mM ammonium sulfate, 0.1% bovine serum albumin, and 0.02% Tween 20). Experiments comparing class IA PI3K versus class IB PI3Kγ used 50 nM of each class IA PI3K.</p><p>When comparing nanobody binding to phosphorylated and unphosphorylated p110γ, we used a final concentration of 25 nM for both phosphorylated and non-phosphorylated p110γ with association occurring for 600 s, followed by a 600 s dissociation. The K<sub>D</sub> (dissociation constant) for the different p110γ complexes was calculated from the binding curves based on their global fit to a 1:1 binding model using ForteBio data analysis 12.0 (Fortebio Inc).</p></sec><sec id="s4-9"><title>SLB TIRF microscopy experiments</title><p>The membrane binding dynamics of Dy647-p84-p110γ were measured in the absence and presence of nanobody 7 (NB7) using TIRF microscopy. As previously described (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>), SLBs were formed using 50 nm extruded small unilamellar vesicles containing the following lipids: 1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphocholine (18:1 DOPC, Avanti #850375C), 1,2-dioleoyl-<italic>sn-</italic>glycero-3-phospho-L-serine (18:1 DOPS, Avanti #840035C), 1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine-<italic>N</italic>-[4-(p-maleimidomethyl)cyclohexane-carboxamide] (18:1 MCC-PE, Avanti #780201C). Lipid compositions reported in figure legends represent the molar percentage of each lipid species.</p><p>To create SLBs, a total concentration of 0.25 mM lipids was solvated in 1× PBS (pH 7.4) and deposited on Piranha etched glass coverslips (25×75 mm) adhered to an IBIDI chamber. After a 30 min incubation, membranes were washed with 4 mL of 1× PBS (pH 7.4) and then blocked for 10 min with 1 mg/mL beta casein (Thermo Fisher Science, Cat#37528) in 1× PBS (pH 7.4) (Corning, Cat#46-013CM). To conjugate H-Ras to maleimide lipids (MCC-PE), blocked membranes were incubated with 30 µM H-Ras (GDP) in buffer containing 1× PBS (pH 7.4), 1 mM MgCl<sub>2</sub>, 50 µM GDP, and 0.1 mM TCEP for 2 hr. The membrane conjugation reaction was terminated after 2 hr with 1× PBS (pH 7.4) containing 5 mM β-ME. Membranes were then washed and stored in 1× PBS (pH 7.4) until performing the TIRF microscopy (TIRF-M) membrane binding experiments. H-Ras was purified as previously described (<xref ref-type="bibr" rid="bib51">Rathinaswamy et al., 2023</xref>).</p><p>To perform the TIRF-M membrane binding assays, 200 nM farnesyl-<italic>Gβγ</italic> was equilibrated into the supported membranes for 30 min. In parallel, nucleotide exchange of H-Ras (GDP) was performed by adding 50 nM guanine nucleotide exchange factor (SosCat) in 1× PBS (pH 7.4), 1 mM MgCl<sub>2</sub>, 50 µM GDP. To measure membrane binding, Dy647-p84-p110γ was diluted into the following buffer: 20 mM HEPES (pH 7.0), 150 mM NaCl, 50 µM GTP, 1 mM ATP, 5 mM MgCl<sub>2</sub>, 0.5 mM EGTA, 20 mM glucose, 200 µg/mL beta casein (Thermo Scientific, Cat#37528), 20 mM BME, 320 µg/mL glucose oxidase (Serva, #22780.01 <italic>Aspergillus niger</italic>), 50 µg/mL catalase (Sigma, #C40-100MG Bovine Liver), and 2 mM Trolox. Trolox was prepared as previously described (<xref ref-type="bibr" rid="bib21">Hansen et al., 2019</xref>). Perishable reagents (i.e., glucose oxidase, catalase, and Trolox) were added 10 min before image acquisition.</p><p>TIRF-M experiments were performed using an inverted Nikon Ti2 microscope with a 100× Nikon (1.49 NA) oil immersion objective. The x-axis and y-axis positions were controlled using a Nikon motorized stage. Dy647-p84-p110γ was excited with a 637 nm diode laser (OBIS laser diode, Coherent Inc Santa Clara, CA, USA) controlled with an acousto-optic tunable filter and laser launch built by Vortran (Sacramento, CA, USA). The power output measured through the objective for single particle imaging was 1–3 mW. Excitation light passing through quad multi-pass dichroic filter cube (Semrock). Fluorescence emission passed through Nikon emission filter wheel containing the following 25 mm ET700/75 M emission filters (Semrock) before being detected on iXion Life 897 EMCCD camera (Andor Technology Ltd., UK). All TIRF-M experiments were performed at room temperature (23°C). Microscope hardware was controlled using Nikon NIS elements. Data analysis was performed using ImageJ/Fiji and Prism graphing program.</p></sec><sec id="s4-10"><title>Cryo-EM sample preparation and data collection</title><p>Three µL of purified nanobody-bound p110γ at 0.45 mg/mL was adsorbed onto C-Flat 2/2-T grids that were glow discharged for 25 s at 15 mA. Grids were then plunged into liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific) with the following settings: –5 blot force, 1.5 s blot time, 100% humidity, and 4°C. Vitrified specimens were screened for ice and particle quality at the UBC high-resolution macromolecular electron microscopy (HRMEM) facility using a 200 kV Glacios transmission electron microscope equipped with a Falcon 3EC direct electron detector (DED). Clipped grids were sent to the Pacific Northwest Cryo-EM Center (PNCC) where 7322 movies were collected using a Titan Krios equipped with a Gatan K3 DED and a BioQuantum K3 energy filter with a slit width of 20 eV. The movies were collected at a physical pixel size of 0.830 Å/pix and a total dose of 50 e<sup>-</sup>/Å<sup>2</sup> over 50 frames.</p></sec><sec id="s4-11"><title>Cryo-EM image analysis</title><p>The data were processed using cryoSPARC v.3.3.2 (<xref ref-type="bibr" rid="bib46">Punjani et al., 2017</xref>). The movies were pre-processed by patch motion correction using default settings except Fourier cropping by a factor of 2, followed by patch CTF estimation using default settings. A 3D map of PI3K p110γ-p101 complex (EMD-23808) was used to create 2D projections for use as templates to auto-pick 1,463,553 particles. Particles were extracted with a box size of 380 pixels, Fourier cropped to a box size of 96 pixels and subjected to 2D classification. After discarding classes with obvious noise and no features, 795,162 particles were used for multiple rounds of ab initio reconstruction and heterogeneous refinement using four or five classes; 365,178 particles, which generated the two best 3D reconstruction, were used to carry out per-particle local-motion correction with 760 pixels box size later downsized to 380 pixels followed by several rounds of ab initio reconstruction and heterogeneous refinement using three or five classes; and 149,603 from best class were further refined by homogeneous refinement and a final non-uniform-refinement which generated a reconstruction with an overall resolution of 3.02 Å based on the Fourier shell correlation 0.143 criterion.</p></sec><sec id="s4-12"><title>Building the structural model of p110γ-NB7</title><p>The previous structural model of full-length p110γ from the complex of p110γ-p101 (PDB: 7MEZ) (<xref ref-type="bibr" rid="bib48">Rathinaswamy et al., 2021a</xref>) was fit into the map using Chimera (<xref ref-type="bibr" rid="bib45">Pettersen et al., 2004</xref>). A model of the nanobody was generated using Alphafold2 using the Colabfold v1.5.2 server (<xref ref-type="bibr" rid="bib40">Mirdita et al., 2022</xref>). The CDR loops were removed from this initial model, and the remaining nanobody was fit into the map using Chimera. The final structure was built by iterative rounds of automated model building in Phenix, manual model building in COOT (<xref ref-type="bibr" rid="bib18">Emsley et al., 2010</xref>), and refinement in Phenix.real_space_refine using realspace, rigid body, and adp refinement with tight secondary structure restraints (<xref ref-type="bibr" rid="bib1">Afonine et al., 2012</xref>). This allowed for unambiguous building of the CDRs of the nanobody, and their interface with p110γ. The full refinement and validation statistics are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-13"><title>Phosphorylation analysis</title><p>For the dose-response phosphorylation of p110γ, p110γ/p84, and p110γ/p101, each protein or complex (750 nM) was mixed with ATP (200 µM), GFB (20 mM Tris pH 8.5, 100 mM NaCl, 50 mM ammonium sulfate and 0.5 mM TCEP), MgCl<sub>2</sub> (20 mM), and various amounts of PKCβ (4 μg, 800 ng, 160 ng, 32 ng, 6.4 ng, and 0 ng). Reactions were incubated for 3 hr on ice and quenched with 50 µL of ice-cold acidic quench buffer (0.7 M guanidine-HCl, 1% formic acid), followed by immediate freezing using liquid nitrogen and storage at −80°C.</p><p>For the experiment studying the effect of nanobody on phosphorylation, p110γ or p110γ/p101 (500 nM) was mixed with ATP (1 mM), GFB (20 mM Tris pH 8.5, 100 mM NaCl, 50 mM ammonium sulfate, and 0.5 mM TCEP), MgCl<sub>2</sub>(20 mM), with nanobody and PKCβ present at 1200 nM and 500 nM, respectively. Reactions were incubated for 1 hr at room temperature and quenched with 54 µL of ice-cold acidic quench buffer (0.7 M guanidine-HCl, 1% formic acid) followed by immediate freezing using liquid nitrogen and storage at −80°C.</p><p>Phosphorylation of all proteins was confirmed using mass spectrometry and PEAKS7 analysis. The LC-MS analysis of these samples was carried out using the same pipeline as used in the HDX-MS section. The phosphorylated and non-phosphorylated peptide ratios were determined by generating extracted ion chromatograms for each phosphorylated or non-phosphorylated peptide using their molecular formula and charge state in the Bruker Compass Data Analysis software. The area under each extracted curve was then extracted. The full MS quantification of each of the phosphorylated and non-phosphorylated peptide is provided in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p></sec><sec id="s4-14"><title>Hydrogen-deuterium exchange mass spectrometry</title><p>Exchange reactions to assess differences in p110γ upon phosphorylation were carried out at 20°C in 10 µL volumes with final concentrations of 1.6 µM for both apo and phosphorylated p110γ. A total of two conditions were assessed: p110γ apo and PKCβ phosphorylated p110γ. The H/D exchange reaction was initiated by the addition of 8 µL D<sub>2</sub>O buffer (94.3% D<sub>2</sub>O, 100 mM NaCl, 20 mM HEPES pH 7.5) to the 2 µL protein for a final D<sub>2</sub>O concentration of 75.4%. Exchange was carried out over five time points (3 s on ice, and 3 s, 30 s, 300 s, and 3000 s at 20°C) and the reaction was quenched with addition of 60 µL of ice-cold acidic quench buffer (0.7 M guanidine-HCl, 1% formic acid). After quenching, samples were immediately frozen in liquid nitrogen and stored at –80°C. All reactions were carried out in triplicate.</p><sec id="s4-14-1"><title>Protein digestion and MS/MS data collection</title><p>Protein samples for both HDX-MS and phosphorylation analysis were analyzed using the same LC-MS setup. Samples were rapidly thawed and injected onto an integrated fluidics system containing an HDx-3 PAL liquid handling robot and climate-controlled chromatography system (LEAP Technologies), a Dionex Ultimate 3000 UHPLC system, as well as an Impact HD QTOF Mass spectrometer (Bruker). The protein was run over two immobilized pepsin columns (Applied Biosystems; Poroszyme Immobilized Pepsin Cartridge, 2.1 mm × 30 mm; Thermo Fisher 2‐3131‐00; at 10°C and 2°C respectively) at 200 μL/min for 3 min. The resulting peptides were collected and desalted on a C18 trap column (Acquity UPLC BEH C18 1.7 mm column [2.1×5 mm]; Waters 186003975). The trap was subsequently eluted in line with an ACQUITY 1.7 µm particle, 100×1 mm<sup>2</sup> C18 UPLC column (Waters 186002352), using a gradient of 3–35% B (buffer A, 0.1% formic acid; buffer B, 100% acetonitrile) over 11 min immediately followed by a gradient of 35–80% B over 5 min. MS experiments acquired over a mass range from 150 to 2200 mass/charge ratio (m/z) using an electrospray ionization source operated at a temperature of 200°C and a spray voltage of 4.5 kV.</p></sec><sec id="s4-14-2"><title>Peptide identification</title><p>Peptides were identified using data-dependent acquisition following tandem MS/MS experiments (0.5 s precursor scan from 150 to 2000 m/z; twelve 0.25 s fragment scans from 150 to 2000 m/z). MS/MS datasets were analyzed using PEAKS7 (PEAKS), and a false discovery rate was set at 0.1% using a database of purified proteins and known contaminants. The same approach was used to identify phosphorylated and non-phosphorylated peptides for our in vitro phosphorylation experiments, with variable phosphorylation of STY residues was added to the search. The search parameters were set with a precursor tolerance of 20 parts per million, fragment mass error 0.02 Da, and charge states from 1 to 8, with a selection criterion of peptides that had a −10logp score of &gt;24.03 for phosphorylated and &gt;23.05 for non-phosphorylated. The MS/MS spectra of the PKCβ phosphorylated peptides are included in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></sec><sec id="s4-14-3"><title>Mass analysis of peptide centroids and measurement of deuterium incorporation</title><p>HD‐Examiner Software (Sierra Analytics) was used to automatically calculate the level of deuterium incorporation into each peptide. All peptides were manually inspected for correct charge state, correct retention time, and appropriate selection of isotopic distribution. Deuteration levels were calculated using the centroid of the experimental isotope clusters. HDX-MS results are presented with no correction for back exchange shown in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>, with the only correction being applied correcting for the deuterium oxide percentage of the buffer used in the exchange (75.4%). Changes in any peptide at any time point greater than specified cut-offs (5% and 0.45 Da) and with an unpaired, two-tailed t-test value of p&lt;0.01 was considered significant. A number of peptides in the helical domain showed isotope distributions consistent with EX1 H/D exchange. Attempts to define the relative percentages of each population using HDExaminer were extremely noisy, so representative EX1 profiles are shown in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. The raw peptide deuterium incorporation graphs for a selection of peptides with significant differences are shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, with the raw data for all analyzed peptides in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. To allow for visualization of differences across all peptides, we utilized number of deuteron difference (#D) plots (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These plots show the total difference in deuterium incorporation over the entire H/D exchange time course, with each point indicating a single peptide. The data analysis statistics for all HDX-MS experiments are in Appendix 1—key resources table according to the guidelines of <xref ref-type="bibr" rid="bib38">Masson et al., 2019</xref>. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (<xref ref-type="bibr" rid="bib43">Perez-Riverol et al., 2022</xref>) with the dataset identifier PXD040765.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>JEB reports personal fees from Scorpion Therapeutics, Reactive therapeutics and Olema Oncology; and research grants from Novartis</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Cryo electron microscopy (cryo-EM) data collection, refinement, and validation statistics.</title></caption><media xlink:href="elife-88058-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>HDX-MS data collection and validation statistics.</title></caption><media xlink:href="elife-88058-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88058-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw source data for figures.</title></caption><media xlink:href="elife-88058-data1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The model of the nanobody bound p110γ has been deposited in the protein data bank (PDB) with the identifier 8DP0, with the EM data available at the EMDB with the identifier EMD-27627. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (<xref ref-type="bibr" rid="bib43">Perez-Riverol et al., 2022</xref>) with the dataset identifier PXD040765. All source data underlying all data shown in the figures and figure supplements is available in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. All genetic material generated for this study is available from the lead contact by request.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD040765">PXD040765</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Sung</surname><given-names>SE</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Structure of p110 gamma bound to the Ras inhibitory nanobody NB7</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/8DP0">8DP0</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Sung</surname><given-names>SE</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Structure of p110 gamma bound to the Ras inhibitory nanobody NB7</data-title><source>Electron Microscopy Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/emdb/EMD-27627">EMD-27627</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>JEB is supported by the Canadian Institute of Health Research (CIHR, 168998), and the Michael Smith Foundation for Health Research (MSFHR, scholar 17686). CKY is supported by CIHR (FDN-143228, PJT-168907) and the Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-03951). SDH is supported by an NSF CAREER Award (MCB-2048060). This research project was supported in part by the UBC High Resolution Macromolecular Cryo-Electron Microscopy Facility (HRMEM). A portion of this research was supported by NIH grant U24GM129547 and performed at the PNCC at OHSU and accessed through EMSL (grid.436923.9), a DOE Office of Science User Facility sponsored by the Office of Biological and Environmental Research. We appreciate help from Theo Humphreys and Rose Marie Haynes with data collection at PNCC. Competing Interests: The authors declare that they have no competing interests.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Mustyakimov</surname><given-names>M</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Urzhumtsev</surname><given-names>A</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Towards automated crystallographic structure refinement with <italic>phenix.refine</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>68</volume><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id><pub-id pub-id-type="pmid">22505256</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angulo</surname><given-names>I</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Garçon</surname><given-names>F</given-names></name><name><surname>Banham-Hall</surname><given-names>E</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Leahy</surname><given-names>TR</given-names></name><name><surname>Baxendale</surname><given-names>H</given-names></name><name><surname>Coulter</surname><given-names>T</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Blake-Palmer</surname><given-names>K</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Fiddler</surname><given-names>C</given-names></name><name><surname>Juss</surname><given-names>J</given-names></name><name><surname>Cilliers</surname><given-names>D</given-names></name><name><surname>Markelj</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Farmer</surname><given-names>G</given-names></name><name><surname>Kielkowska</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Kracker</surname><given-names>S</given-names></name><name><surname>Debré</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Pellier</surname><given-names>I</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Barcenas-Morales</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Abinun</surname><given-names>M</given-names></name><name><surname>Clatworthy</surname><given-names>M</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Chilvers</surname><given-names>ER</given-names></name><name><surname>Cant</surname><given-names>AJ</given-names></name><name><surname>Kumararatne</surname><given-names>D</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Condliffe</surname><given-names>A</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage</article-title><source>Science</source><volume>342</volume><fpage>866</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1126/science.1243292</pub-id><pub-id pub-id-type="pmid">24136356</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becattini</surname><given-names>B</given-names></name><name><surname>Marone</surname><given-names>R</given-names></name><name><surname>Zani</surname><given-names>F</given-names></name><name><surname>Arsenijevic</surname><given-names>D</given-names></name><name><surname>Seydoux</surname><given-names>J</given-names></name><name><surname>Montani</surname><given-names>J-P</given-names></name><name><surname>Dulloo</surname><given-names>AG</given-names></name><name><surname>Thorens</surname><given-names>B</given-names></name><name><surname>Preitner</surname><given-names>F</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Solinas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance</article-title><source>PNAS</source><volume>108</volume><fpage>E854</fpage><lpage>E863</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106698108</pub-id><pub-id pub-id-type="pmid">21949398</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Sunose</surname><given-names>M</given-names></name><name><surname>Ellard</surname><given-names>K</given-names></name><name><surname>Cansfield</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><name><surname>Ramsden</surname><given-names>N</given-names></name><name><surname>Bergamini</surname><given-names>G</given-names></name><name><surname>Neubauer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>22</volume><fpage>5257</fpage><lpage>5263</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.06.049</pub-id><pub-id pub-id-type="pmid">22819766</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Marone</surname><given-names>R</given-names></name><name><surname>Collmann</surname><given-names>E</given-names></name><name><surname>Calvez</surname><given-names>R</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PI3Kγ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>ra27</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2000259</pub-id><pub-id pub-id-type="pmid">19509406</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Prota</surname><given-names>AE</given-names></name><name><surname>Beaufils</surname><given-names>F</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Melone</surname><given-names>A</given-names></name><name><surname>Inglis</surname><given-names>AJ</given-names></name><name><surname>Rageot</surname><given-names>D</given-names></name><name><surname>Sele</surname><given-names>AM</given-names></name><name><surname>Cmiljanovic</surname><given-names>V</given-names></name><name><surname>Cmiljanovic</surname><given-names>N</given-names></name><name><surname>Bargsten</surname><given-names>K</given-names></name><name><surname>Aher</surname><given-names>A</given-names></name><name><surname>Akhmanova</surname><given-names>A</given-names></name><name><surname>Díaz</surname><given-names>JF</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Zvelebil</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Steinmetz</surname><given-names>MO</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14683</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14683</pub-id><pub-id pub-id-type="pmid">28276440</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breasson</surname><given-names>L</given-names></name><name><surname>Becattini</surname><given-names>B</given-names></name><name><surname>Sardi</surname><given-names>C</given-names></name><name><surname>Molinaro</surname><given-names>A</given-names></name><name><surname>Zani</surname><given-names>F</given-names></name><name><surname>Marone</surname><given-names>R</given-names></name><name><surname>Botindari</surname><given-names>F</given-names></name><name><surname>Bousquenaud</surname><given-names>M</given-names></name><name><surname>Ruegg</surname><given-names>C</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Solinas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity</article-title><source>Science Signaling</source><volume>10</volume><elocation-id>eaaf2969</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaf2969</pub-id><pub-id pub-id-type="pmid">28720716</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Berndt</surname><given-names>A</given-names></name><name><surname>Finegan</surname><given-names>T</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dynamics of the phosphoinositide 3-kinase p110δ Interaction with p85α and membranes reveals aspects of regulation distinct from p110α</article-title><source>Structure</source><volume>19</volume><fpage>1127</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.06.003</pub-id><pub-id pub-id-type="pmid">21827948</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Masson</surname><given-names>GR</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase P110Α (Pik3Ca)</article-title><source>PNAS</source><volume>109</volume><fpage>15259</fpage><lpage>15264</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205508109</pub-id><pub-id pub-id-type="pmid">22949682</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS)</article-title><source>Advances in Biological Regulation</source><volume>53</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.jbior.2012.09.005</pub-id><pub-id pub-id-type="pmid">23194976</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synergy in activating class I PI3Ks</article-title><source>Trends in Biochemical Sciences</source><volume>40</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.12.003</pub-id><pub-id pub-id-type="pmid">25573003</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural basis for regulation of phosphoinositide kinases and their involvement in human disease</article-title><source>Molecular Cell</source><volume>71</volume><fpage>653</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.005</pub-id><pub-id pub-id-type="pmid">30193094</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campa</surname><given-names>CC</given-names></name><name><surname>Silva</surname><given-names>RL</given-names></name><name><surname>Margaria</surname><given-names>JP</given-names></name><name><surname>Pirali</surname><given-names>T</given-names></name><name><surname>Mattos</surname><given-names>MS</given-names></name><name><surname>Kraemer</surname><given-names>LR</given-names></name><name><surname>Reis</surname><given-names>DC</given-names></name><name><surname>Grosa</surname><given-names>G</given-names></name><name><surname>Copperi</surname><given-names>F</given-names></name><name><surname>Dalmarco</surname><given-names>EM</given-names></name><name><surname>Lima-Júnior</surname><given-names>RCP</given-names></name><name><surname>Aprile</surname><given-names>S</given-names></name><name><surname>Sala</surname><given-names>V</given-names></name><name><surname>Dal Bello</surname><given-names>F</given-names></name><name><surname>Prado</surname><given-names>DS</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Medana</surname><given-names>C</given-names></name><name><surname>Cassali</surname><given-names>GD</given-names></name><name><surname>Tron</surname><given-names>GC</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><name><surname>Ciraolo</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>RC</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>5232</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07698-6</pub-id><pub-id pub-id-type="pmid">30542075</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>Rückle</surname><given-names>T</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Ardissone</surname><given-names>V</given-names></name><name><surname>Rintelen</surname><given-names>F</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Ferrandi</surname><given-names>C</given-names></name><name><surname>Chabert</surname><given-names>C</given-names></name><name><surname>Gillieron</surname><given-names>C</given-names></name><name><surname>Françon</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Gretener</surname><given-names>D</given-names></name><name><surname>Perrin</surname><given-names>D</given-names></name><name><surname>Leroy</surname><given-names>D</given-names></name><name><surname>Vitte</surname><given-names>PA</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Cirillo</surname><given-names>R</given-names></name><name><surname>Schwarz</surname><given-names>MK</given-names></name><name><surname>Rommel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis</article-title><source>Nature Medicine</source><volume>11</volume><fpage>936</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1038/nm1284</pub-id><pub-id pub-id-type="pmid">16127437</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Henau</surname><given-names>O</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>D</given-names></name><name><surname>Campesato</surname><given-names>LF</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Cymerman</surname><given-names>DH</given-names></name><name><surname>Budhu</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Pink</surname><given-names>M</given-names></name><name><surname>Tchaicha</surname><given-names>J</given-names></name><name><surname>Douglas</surname><given-names>M</given-names></name><name><surname>Tibbitts</surname><given-names>T</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Proctor</surname><given-names>J</given-names></name><name><surname>Kosmider</surname><given-names>N</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Stern</surname><given-names>H</given-names></name><name><surname>Soglia</surname><given-names>J</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>McGovern</surname><given-names>K</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells</article-title><source>Nature</source><volume>539</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature20554</pub-id><pub-id pub-id-type="pmid">27828943</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deladeriere</surname><given-names>A</given-names></name><name><surname>Gambardella</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The regulatory subunits of PI3Kγ control distinct neutrophil responses</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra8</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005564</pub-id><pub-id pub-id-type="pmid">25605974</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dornan</surname><given-names>GL</given-names></name><name><surname>Siempelkamp</surname><given-names>BD</given-names></name><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Pik3Cd and Pik3R1</article-title><source>PNAS</source><volume>114</volume><fpage>1982</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617244114</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of <italic>Coot</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lescarbeau</surname><given-names>A</given-names></name><name><surname>Nair</surname><given-names>SJ</given-names></name><name><surname>Grenier</surname><given-names>L</given-names></name><name><surname>Pradeilles</surname><given-names>JA</given-names></name><name><surname>Glenadel</surname><given-names>Q</given-names></name><name><surname>Tibbitts</surname><given-names>T</given-names></name><name><surname>Rowley</surname><given-names>AM</given-names></name><name><surname>DiNitto</surname><given-names>JP</given-names></name><name><surname>Brophy</surname><given-names>EE</given-names></name><name><surname>O’Hearn</surname><given-names>EL</given-names></name><name><surname>Ali</surname><given-names>JA</given-names></name><name><surname>Winkler</surname><given-names>DG</given-names></name><name><surname>Goldstein</surname><given-names>SI</given-names></name><name><surname>O’Hearn</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>CM</given-names></name><name><surname>Hoyt</surname><given-names>JG</given-names></name><name><surname>Soglia</surname><given-names>JR</given-names></name><name><surname>Cheung</surname><given-names>C</given-names></name><name><surname>Pink</surname><given-names>MM</given-names></name><name><surname>Proctor</surname><given-names>JL</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Tremblay</surname><given-names>MR</given-names></name><name><surname>Castro</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Discovery of a selective Phosphoinositide-3-kinase (PI3K)-Γ inhibitor (IPI-549) as an immuno-oncology clinical candidate</article-title><source>ACS Medicinal Chemistry Letters</source><volume>7</volume><fpage>862</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.6b00238</pub-id><pub-id pub-id-type="pmid">27660692</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangadhara</surname><given-names>G</given-names></name><name><surname>Dahl</surname><given-names>G</given-names></name><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Rae</surname><given-names>R</given-names></name><name><surname>Gunnarsson</surname><given-names>J</given-names></name><name><surname>Blaho</surname><given-names>S</given-names></name><name><surname>Öster</surname><given-names>L</given-names></name><name><surname>Lindmark</surname><given-names>H</given-names></name><name><surname>Karabelas</surname><given-names>K</given-names></name><name><surname>Pemberton</surname><given-names>N</given-names></name><name><surname>Tyrchan</surname><given-names>C</given-names></name><name><surname>Mogemark</surname><given-names>M</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Perry</surname><given-names>MWD</given-names></name><name><surname>Papavoine</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A class of highly selective inhibitors bind to an active state of PI3Kγ</article-title><source>Nature Chemical Biology</source><volume>15</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0215-0</pub-id><pub-id pub-id-type="pmid">30718815</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>SD</given-names></name><name><surname>Huang</surname><given-names>WYC</given-names></name><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Bieling</surname><given-names>P</given-names></name><name><surname>Christensen</surname><given-names>SM</given-names></name><name><surname>Groves</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stochastic geometry sensing and polarization in a lipid kinase-phosphatase competitive reaction</article-title><source>PNAS</source><volume>116</volume><fpage>15013</fpage><lpage>15022</lpage><pub-id pub-id-type="doi">10.1073/pnas.1901744116</pub-id><pub-id pub-id-type="pmid">31278151</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PI3K signalling in inflammation</article-title><source>Biochimica et Biophysica Acta</source><volume>1851</volume><fpage>882</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2014.12.006</pub-id><pub-id pub-id-type="pmid">25514767</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Ranga-Prasad</surname><given-names>H</given-names></name><name><surname>Parson</surname><given-names>MAH</given-names></name><name><surname>Harris</surname><given-names>NJ</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Oncogenic mutations of PIk3Ca lead to increased membrane recruitment driven by reorientation of the ABD, P85 and C-terminus</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-35789-6</pub-id><pub-id pub-id-type="pmid">36635288</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>JR</given-names></name><name><surname>Gogvadze</surname><given-names>E</given-names></name><name><surname>Xavier</surname><given-names>AR</given-names></name><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Voelzmann</surname><given-names>J</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PI3Kγ regulatory protein p84 determines mast cell sensitivity to Ras inhibition—Moving towards cell specific PI3K targeting?</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>585070</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.585070</pub-id><pub-id pub-id-type="pmid">33193405</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Wardwell</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Emery</surname><given-names>CM</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Murray</surname><given-names>RR</given-names></name><name><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Alkan</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</article-title><source>Nature</source><volume>468</volume><fpage>968</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/nature09627</pub-id><pub-id pub-id-type="pmid">21107320</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>MM</given-names></name><name><surname>Messer</surname><given-names>KS</given-names></name><name><surname>Ralainirina</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Leem</surname><given-names>CJ</given-names></name><name><surname>Gorjestani</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>AV</given-names></name><name><surname>Figueiredo</surname><given-names>CC</given-names></name><name><surname>Foubert</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>MC</given-names></name><name><surname>Pink</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>DG</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Kutok</surname><given-names>J</given-names></name><name><surname>McGovern</surname><given-names>K</given-names></name><name><surname>Frazer</surname><given-names>KA</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Sasik</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>EEW</given-names></name><name><surname>Varner</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Pi3Kγ is a molecular switch that controls immune suppression</article-title><source>Nature</source><volume>539</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nature19834</pub-id><pub-id pub-id-type="pmid">27642729</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>MM</given-names></name><name><surname>Cappello</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>AV</given-names></name><name><surname>Ralainirina</surname><given-names>N</given-names></name><name><surname>Hardamon</surname><given-names>CR</given-names></name><name><surname>Foubert</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>MC</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Mose</surname><given-names>E</given-names></name><name><surname>Bouvet</surname><given-names>M</given-names></name><name><surname>Lowy</surname><given-names>AM</given-names></name><name><surname>Valasek</surname><given-names>MA</given-names></name><name><surname>Sasik</surname><given-names>R</given-names></name><name><surname>Novelli</surname><given-names>F</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Varner</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>870</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1346</pub-id><pub-id pub-id-type="pmid">27179037</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurig</surname><given-names>B</given-names></name><name><surname>Shymanets</surname><given-names>A</given-names></name><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Prajwal</surname><given-names>BC</given-names></name><name><surname>Ahmadian</surname><given-names>MR</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Gohla</surname><given-names>A</given-names></name><name><surname>Harteneck</surname><given-names>C</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Jeanclos</surname><given-names>E</given-names></name><name><surname>Nürnberg</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110γ</article-title><source>PNAS</source><volume>106</volume><fpage>20312</fpage><lpage>20317</lpage><pub-id pub-id-type="doi">10.1073/pnas.0905506106</pub-id><pub-id pub-id-type="pmid">19906996</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laffargue</surname><given-names>M</given-names></name><name><surname>Calvez</surname><given-names>R</given-names></name><name><surname>Finan</surname><given-names>P</given-names></name><name><surname>Trifilieff</surname><given-names>A</given-names></name><name><surname>Barbier</surname><given-names>M</given-names></name><name><surname>Altruda</surname><given-names>F</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function</article-title><source>Immunity</source><volume>16</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00282-0</pub-id><pub-id pub-id-type="pmid">11911828</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanahan</surname><given-names>SM</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Lucas</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of Pi3Kγ in the immune system: new insights and translational implications</article-title><source>Nature Reviews. Immunology</source><volume>22</volume><fpage>687</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00701-8</pub-id><pub-id pub-id-type="pmid">35322259</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title><source>Nature</source><volume>505</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12912</pub-id><pub-id pub-id-type="pmid">24390350</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Smrcka</surname><given-names>AV</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction</article-title><source>Science</source><volume>287</volume><fpage>1046</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1126/science.287.5455.1046</pub-id><pub-id pub-id-type="pmid">10669417</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Prever</surname><given-names>L</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Gulluni</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting PI3K/AKT/mTOR signaling pathway in breast cancer</article-title><source>Cancers</source><volume>13</volume><elocation-id>3517</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13143517</pub-id><pub-id pub-id-type="pmid">34298731</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hart</surname><given-names>JR</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name><name><surname>Wang</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cryo-EM structures of cancer-specific Helical and kinase domain mutations of PI3Kα</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2215621119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2215621119</pub-id><pub-id pub-id-type="pmid">36343266</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Niemela</surname><given-names>JE</given-names></name><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Moens</surname><given-names>L</given-names></name><name><surname>Cannons</surname><given-names>JL</given-names></name><name><surname>Biancalana</surname><given-names>M</given-names></name><name><surname>Stoddard</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Frucht</surname><given-names>DM</given-names></name><name><surname>Rao</surname><given-names>VK</given-names></name><name><surname>Atkinson</surname><given-names>TP</given-names></name><name><surname>Agharahimi</surname><given-names>A</given-names></name><name><surname>Hussey</surname><given-names>AA</given-names></name><name><surname>Folio</surname><given-names>LR</given-names></name><name><surname>Olivier</surname><given-names>KN</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Oliveira</surname><given-names>JB</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</article-title><source>Nature Immunology</source><volume>15</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/ni.2771</pub-id><pub-id pub-id-type="pmid">24165795</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Wall</surname><given-names>AA</given-names></name><name><surname>Tong</surname><given-names>SJ</given-names></name><name><surname>Hung</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Tarique</surname><given-names>AA</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name><name><surname>Fantino</surname><given-names>E</given-names></name><name><surname>Marzolo</surname><given-names>MP</given-names></name><name><surname>Stow</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TLR Crosstalk activates Lrp1 to recruit Rab8A and PI3Kγ for suppression of inflammatory responses</article-title><source>Cell Reports</source><volume>24</volume><fpage>3033</fpage><lpage>3044</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.028</pub-id><pub-id pub-id-type="pmid">30208326</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandelker</surname><given-names>D</given-names></name><name><surname>Gabelli</surname><given-names>SB</given-names></name><name><surname>Schmidt-Kittler</surname><given-names>O</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Cheong</surname><given-names>I</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Amzel</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane</article-title><source>PNAS</source><volume>106</volume><fpage>16996</fpage><lpage>17001</lpage><pub-id pub-id-type="doi">10.1073/pnas.0908444106</pub-id><pub-id pub-id-type="pmid">19805105</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>GR</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name><name><surname>Anand</surname><given-names>GS</given-names></name><name><surname>Borchers</surname><given-names>C</given-names></name><name><surname>Brier</surname><given-names>S</given-names></name><name><surname>Bou-Assaf</surname><given-names>GM</given-names></name><name><surname>Engen</surname><given-names>JR</given-names></name><name><surname>Englander</surname><given-names>SW</given-names></name><name><surname>Faber</surname><given-names>J</given-names></name><name><surname>Garlish</surname><given-names>R</given-names></name><name><surname>Griffin</surname><given-names>PR</given-names></name><name><surname>Gross</surname><given-names>ML</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Hamuro</surname><given-names>Y</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Houde</surname><given-names>D</given-names></name><name><surname>Iacob</surname><given-names>RE</given-names></name><name><surname>Jørgensen</surname><given-names>TJD</given-names></name><name><surname>Kaltashov</surname><given-names>IA</given-names></name><name><surname>Klinman</surname><given-names>JP</given-names></name><name><surname>Konermann</surname><given-names>L</given-names></name><name><surname>Man</surname><given-names>P</given-names></name><name><surname>Mayne</surname><given-names>L</given-names></name><name><surname>Pascal</surname><given-names>BD</given-names></name><name><surname>Reichmann</surname><given-names>D</given-names></name><name><surname>Skehel</surname><given-names>M</given-names></name><name><surname>Snijder</surname><given-names>J</given-names></name><name><surname>Strutzenberg</surname><given-names>TS</given-names></name><name><surname>Underbakke</surname><given-names>ES</given-names></name><name><surname>Wagner</surname><given-names>C</given-names></name><name><surname>Wales</surname><given-names>TE</given-names></name><name><surname>Walters</surname><given-names>BT</given-names></name><name><surname>Weis</surname><given-names>DD</given-names></name><name><surname>Wilson</surname><given-names>DJ</given-names></name><name><surname>Wintrode</surname><given-names>PL</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Schriemer</surname><given-names>DC</given-names></name><name><surname>Rand</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments</article-title><source>Nature Methods</source><volume>16</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0459-y</pub-id><pub-id pub-id-type="pmid">31249422</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miled</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Hon</surname><given-names>WC</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Zvelebil</surname><given-names>M</given-names></name><name><surname>Inbar</surname><given-names>Y</given-names></name><name><surname>Schneidman-Duhovny</surname><given-names>D</given-names></name><name><surname>Wolfson</surname><given-names>HJ</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit</article-title><source>Science</source><volume>317</volume><fpage>239</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1126/science.1135394</pub-id><pub-id pub-id-type="pmid">17626883</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>Schütze</surname><given-names>K</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Colabfold: making protein folding accessible to all</article-title><source>Nature Methods</source><volume>19</volume><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id><pub-id pub-id-type="pmid">35637307</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okkenhaug</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Signaling by the Phosphoinositide 3-kinase family in immune cells</article-title><source>Annual Review of Immunology</source><volume>31</volume><fpage>675</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095946</pub-id><pub-id pub-id-type="pmid">23330955</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacold</surname><given-names>ME</given-names></name><name><surname>Suire</surname><given-names>S</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Lara-Gonzalez</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>CT</given-names></name><name><surname>Walker</surname><given-names>EH</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Eccleston</surname><given-names>JF</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma</article-title><source>Cell</source><volume>103</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)00196-3</pub-id><pub-id pub-id-type="pmid">11136978</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><name><surname>García-Seisdedos</surname><given-names>D</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Kamatchinathan</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Frericks-Zipper</surname><given-names>A</given-names></name><name><surname>Eisenacher</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id><pub-id pub-id-type="pmid">34723319</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perino</surname><given-names>A</given-names></name><name><surname>Ghigo</surname><given-names>A</given-names></name><name><surname>Ferrero</surname><given-names>E</given-names></name><name><surname>Morello</surname><given-names>F</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name><name><surname>Baillie</surname><given-names>GS</given-names></name><name><surname>Damilano</surname><given-names>F</given-names></name><name><surname>Dunlop</surname><given-names>AJ</given-names></name><name><surname>Pawson</surname><given-names>C</given-names></name><name><surname>Walser</surname><given-names>R</given-names></name><name><surname>Levi</surname><given-names>R</given-names></name><name><surname>Altruda</surname><given-names>F</given-names></name><name><surname>Silengo</surname><given-names>L</given-names></name><name><surname>Langeberg</surname><given-names>LK</given-names></name><name><surname>Neubauer</surname><given-names>G</given-names></name><name><surname>Heymans</surname><given-names>S</given-names></name><name><surname>Lembo</surname><given-names>G</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Wetzker</surname><given-names>R</given-names></name><name><surname>Houslay</surname><given-names>MD</given-names></name><name><surname>Iaccarino</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Integrating cardiac Pip3 and cAMP signaling through a PKA anchoring function of p110Γ</article-title><source>Molecular Cell</source><volume>42</volume><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.01.030</pub-id><pub-id pub-id-type="pmid">21474070</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: Algorithms for rapid unsupervised Cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Class I Phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease</article-title><source>Advances in Biological Regulation</source><volume>75</volume><elocation-id>100657</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbior.2019.100657</pub-id><pub-id pub-id-type="pmid">31611073</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Fleming</surname><given-names>KD</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Stariha</surname><given-names>JTB</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Baek</surname><given-names>M</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>SD</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Structure of the phosphoinositide 3-kinase (PI3K) P110Γ-P101 complex reveals molecular mechanism of GPCR activation</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabj4282</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abj4282</pub-id><pub-id pub-id-type="pmid">34452907</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Fleming</surname><given-names>KD</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>NJ</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>HDX-MS-Optimized approach to characterize Nanobodies as tools for biochemical and structural studies of class IB phosphoinositide 3-kinases</article-title><source>Structure</source><volume>29</volume><fpage>1371</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1016/j.str.2021.07.002</pub-id><pub-id pub-id-type="pmid">34348129</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Gaieb</surname><given-names>Z</given-names></name><name><surname>Fleming</surname><given-names>KD</given-names></name><name><surname>Borsari</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>NJ</given-names></name><name><surname>Moeller</surname><given-names>BE</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Amaro</surname><given-names>RE</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2021">2021c</year><article-title>Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors</article-title><source>eLife</source><volume>10</volume><elocation-id>e64691</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64691</pub-id><pub-id pub-id-type="pmid">33661099</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Duewell</surname><given-names>BR</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Harris</surname><given-names>NJ</given-names></name><name><surname>Evans</surname><given-names>JT</given-names></name><name><surname>Stariha</surname><given-names>JTB</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Fleming</surname><given-names>KD</given-names></name><name><surname>Ranga-Prasad</surname><given-names>H</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Hansen</surname><given-names>SD</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRs</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>112172</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112172</pub-id><pub-id pub-id-type="pmid">36842083</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>X</given-names></name><name><surname>Gouet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Deciphering key features in protein structures with the new ENDscript server</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>W320</fpage><lpage>W324</lpage><pub-id pub-id-type="doi">10.1093/nar/gku316</pub-id><pub-id pub-id-type="pmid">24753421</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rynkiewicz</surname><given-names>NK</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Suire</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>DM</given-names></name><name><surname>Karanasios</surname><given-names>E</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Oxley</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gβγ is a direct regulator of endogenous P101/P110Γ and P84/P110Γ Pi3Kγ complexes in mouse neutrophils</article-title><source>Science Signaling</source><volume>13</volume><elocation-id>eaaz4003</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaz4003</pub-id><pub-id pub-id-type="pmid">33144519</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Silliman</surname><given-names>N</given-names></name><name><surname>Ptak</surname><given-names>J</given-names></name><name><surname>Szabo</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Gazdar</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>SM</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Willson</surname><given-names>JKV</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>High frequency of mutations of the <italic>PIK3CA</italic> gene in human cancers</article-title><source>Science</source><volume>304</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1126/science.1096502</pub-id><pub-id pub-id-type="pmid">15016963</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shymanets</surname><given-names>A</given-names></name><name><surname>Bucher</surname><given-names>K</given-names></name><name><surname>Beer-Hammer</surname><given-names>S</given-names></name><name><surname>Harteneck</surname><given-names>C</given-names></name><name><surname>Nürnberg</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>P87 and P101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>31059</fpage><lpage>31068</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.508234</pub-id><pub-id pub-id-type="pmid">24014027</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siempelkamp</surname><given-names>BD</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular mechanism of activation of class IA phosphoinositide 3-kinases (Pi3Ks) by membrane-localized HRas</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>12256</fpage><lpage>12266</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.789263</pub-id><pub-id pub-id-type="pmid">28515318</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Eguinoa</surname><given-names>A</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Lui</surname><given-names>M</given-names></name><name><surname>Cooke</surname><given-names>F</given-names></name><name><surname>Coadwell</surname><given-names>J</given-names></name><name><surname>Smrcka</surname><given-names>AS</given-names></name><name><surname>Thelen</surname><given-names>M</given-names></name><name><surname>Cadwallader</surname><given-names>K</given-names></name><name><surname>Tempst</surname><given-names>P</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101</article-title><source>Cell</source><volume>89</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80187-7</pub-id><pub-id pub-id-type="pmid">9094719</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>AJ</given-names></name><name><surname>Maher</surname><given-names>TJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lanahan</surname><given-names>SM</given-names></name><name><surname>Bucklin</surname><given-names>ML</given-names></name><name><surname>Compton</surname><given-names>SR</given-names></name><name><surname>Tyler</surname><given-names>PM</given-names></name><name><surname>Comrie</surname><given-names>WA</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Olivier</surname><given-names>KN</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>McElwee</surname><given-names>JJ</given-names></name><name><surname>Long Priel</surname><given-names>DA</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Mustillo</surname><given-names>PJ</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Koneti Rao</surname><given-names>V</given-names></name><name><surname>Lucas</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue Immunopathology</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4364</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12311-5</pub-id><pub-id pub-id-type="pmid">31554793</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Dbouk</surname><given-names>HA</given-names></name><name><surname>Shymanets</surname><given-names>A</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Abi Saab</surname><given-names>WF</given-names></name><name><surname>Khalil</surname><given-names>BD</given-names></name><name><surname>Harteneck</surname><given-names>C</given-names></name><name><surname>Bresnick</surname><given-names>AR</given-names></name><name><surname>Nürnberg</surname><given-names>B</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs)</article-title><source>PNAS</source><volume>110</volume><fpage>18862</fpage><lpage>18867</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304801110</pub-id><pub-id pub-id-type="pmid">24190998</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Perry</surname><given-names>MWD</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>André</surname><given-names>F</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PI3K inhibitors are finally coming of age</article-title><source>Nature Reviews. Drug Discovery</source><volume>20</volume><fpage>741</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00209-1</pub-id><pub-id pub-id-type="pmid">34127844</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasan</surname><given-names>N</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy</article-title><source>Nature Reviews. Clinical Oncology</source><volume>19</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00633-1</pub-id><pub-id pub-id-type="pmid">35484287</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>EH</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Ried</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Structural insights into phosphoinositide 3-kinase catalysis and signalling</article-title><source>Nature</source><volume>402</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/46319</pub-id><pub-id pub-id-type="pmid">10580505</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walser</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Gogvadze</surname><given-names>E</given-names></name><name><surname>Bohnacker</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hess</surname><given-names>D</given-names></name><name><surname>Küenzi</surname><given-names>P</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Laffargue</surname><given-names>M</given-names></name><name><surname>Wymann</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PKCβ phosphorylates Pi3Kγ to activate it and release it from GPCR control</article-title><source>PLOS Biology</source><volume>11</volume><elocation-id>e1001587</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001587</pub-id><pub-id pub-id-type="pmid">23824069</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structure of lipid kinase P110Β/P85Β elucidates an unusual Sh2-domain-mediated inhibitory mechanism</article-title><source>Molecular Cell</source><volume>41</volume><fpage>567</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.01.026</pub-id><pub-id pub-id-type="pmid">21362552</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom"><italic>E. coli</italic> XL10-GOLD KanR Ultracompetent Cells</td><td align="left" valign="bottom">Agilent</td><td align="char" char="." valign="bottom">200317</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">BL21 <italic>E. coli</italic> C41 (DE3) RIPL</td><td align="left" valign="bottom">PMID: 24876499</td><td align="left" valign="bottom">C41</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Spodoptera frugiperda</italic>)</td><td align="left" valign="bottom">Sf9 Insect Cells</td><td align="left" valign="bottom">Expression systems</td><td align="char" char="ndash" valign="bottom">94-001S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom"><italic>E. coli</italic> DH10EMBacY Competent Cells</td><td align="left" valign="bottom">Geneva Biotech</td><td align="left" valign="bottom">DH10EMBacY</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMultiBac-Gβ1/Gγ2</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">pOP737</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pACEBac1-hsp110γ</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">MR30</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMultiBac-hsp110γ-ssp101</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">MR22</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMultiBac-hsp110γ-mmp84</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">MR24</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pFastBac HRas G12V</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">BS9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">biGBac hsp110γ/ybbr-hsp84</td><td align="left" valign="bottom">PMID:36842083</td><td align="left" valign="bottom">HP28</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">biGBac hsp110γ/ybbr-hsp101</td><td align="left" valign="bottom">PMID:36842083</td><td align="left" valign="bottom">HP29</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">his6-GST-PrescissionProtease-SNAP-RBD(K65E)</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">pSH936</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">his6TEV-HRas(1-184aa) C118S, C181S</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">pSH414</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">his6-G2, SNAP-G1 (DUAL FastBac)</td><td align="left" valign="bottom">PMID:34452907</td><td align="left" valign="bottom">pSH651</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pACEBAC-PKCβII (internal tev cleavage site)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">pMR56</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pFASTBac p110α</td><td align="left" valign="bottom">PMID: 28515318</td><td align="left" valign="bottom">pOV1181</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pFASTBac p110β</td><td align="left" valign="bottom">PMID: 28515318</td><td align="left" valign="bottom">pOV1182</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pFASTBac p110δ</td><td align="left" valign="bottom">PMID: 28515318</td><td align="left" valign="bottom">pOV1183</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pFASTBac p85β</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">EX21</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Fwd primer for amplifying KD of PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR51F</td><td align="left" valign="bottom"><named-content content-type="sequence">GTATTTTCAGGGC</named-content>gccggtaccACGA<break/>CCAACACTGTCTCCAAATTTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Rvs primer for amplifying KD of PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR51R</td><td align="left" valign="bottom">gactcgagcggccgcTTATAGCTCTT<break/>GACTTCGGGTTTTAAAAATTCAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Fwd primer for amplifying N term of PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR52F</td><td align="left" valign="bottom">CCATCACggatctggcggtagt<break/>ATGGCTGACCCGGCTGCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Rvs primer for amplifying N term of PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR52R</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCTGAAAATACAGGTTTTCCTTTTCTTCCGGGACCTTGGTTCCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Fwd primer for adding stop codon to PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR56F</td><td align="left" valign="bottom"><named-content content-type="sequence">AGTCAAGAGCTAA</named-content>gcgg<break/>ccgctcgagtctagagcctgc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Rvs primer for adding stop codon to PKCII</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MR56R</td><td align="left" valign="bottom">gactcgagcggccgcTTAGCTCTTGA<break/>CTTCGGGTTTTAAAAATTCAG</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Transcreener ADP2 FI Assay (1000 Assay, 384 Well)</td><td align="left" valign="bottom">BellBrook Labs</td><td align="char" char="ndash" valign="bottom">3013-1K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Deuterium oxide 99.9%</td><td align="left" valign="bottom">Sigma</td><td align="char" char="." valign="bottom">151882</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Guanosine 5′-diphosphate (GDP) sodium salt hydrate</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">G7127-100MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Guanosine 5′-triphosphate (GTP) sodium salt hydrate</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">G8877-250MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium deoxycholate</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">D6750</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polyoxyethylene (10) lauryl ether</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">P9769</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CHAPS, Molecular Biology Grade</td><td align="left" valign="bottom">EMD Millipore</td><td align="char" char="." valign="bottom">220201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatidylserine (Porcine Brain)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">840032C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatidylethanolamine (Egg yolk)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">P6386</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cholesterol</td><td align="left" valign="bottom">Sigma</td><td align="char" char="." valign="bottom">47,127U</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatidylcholine (Egg yolk)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">840051C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatidylinositol-4,5-bisphosphate (Porcine Brain)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">840046</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sphingomyelin (Egg yolk)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">S0756</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,2-Dioleoyl-<italic>sn</italic>-glycero-3-phosphocholine (DOPC)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">850375C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,2-Dioleoyl-<italic>sn-</italic>glycero-3-phospho-L-serine (18:1, DOPS)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">840035C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,2-Dioleoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine-<italic>N</italic>-[4-(p-maleimidomethyl)cyclohexane-carboxamide] (18:1 MCC-PE)</td><td align="left" valign="bottom">Avanti</td><td align="char" char="." valign="bottom">780201C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">10 mg/mL beta casein solution</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">37528</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">10× PBS (pH 7.4)</td><td align="left" valign="bottom">Corning</td><td align="char" char="ndash" valign="bottom">46-013CM</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">glucose oxidase from <italic>Aspergillus niger</italic> (225 U/mg)</td><td align="left" valign="bottom">Biophoretics</td><td align="left" valign="bottom">B01357.02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Catalase</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">C40-100MG Bovine Liver</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trolox</td><td align="left" valign="bottom">Cayman Chemicals</td><td align="char" char="." valign="bottom">10011659</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dyomics 647 maleimide dye</td><td align="left" valign="bottom">Dyomics</td><td align="char" char="hyphen" valign="bottom">647P1-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Coenzyme A</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">C3019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sulfuric acid</td><td align="left" valign="bottom">Sigma</td><td align="char" char="ndash" valign="bottom">58105-2.5L-PC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">COOT-0.9.4.1</td><td align="left" valign="bottom">CCP4</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phenix-1.19.1</td><td align="left" valign="bottom">Open source</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.phenix-online.org/">https://www.phenix-online.org/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PDBePISA (Proteins, Interfaces, Structures and Assemblies)</td><td align="left" valign="bottom">EMBL-EBI</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pdbe/pisa/pistart.html">https://www.ebi.ac.uk/pdbe/pisa/pistart.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ESPript 3.0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Robert and Gouet, 2014</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://espript.ibcp.fr">https://espript.ibcp.fr</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">HDExaminer</td><td align="left" valign="bottom">Sierra Analytics</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://massspec.com/hdexaminer">http://massspec.com/hdexaminer</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 7</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PyMOL</td><td align="left" valign="bottom">Schroedinger</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://pymol.org">http://pymol.org</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Compass Data Analysis</td><td align="left" valign="bottom">Bruker</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.bruker.com">https://www.bruker.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ChimeraX</td><td align="left" valign="bottom">UCSF</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.rbvi.ucsf.edu/chimerax/">https://www.rbvi.ucsf.edu/chimerax/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ/Fiji</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/software/fiji/">https://imagej.net/software/fiji/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Nikon NIS elements</td><td align="left" valign="bottom">Nikon</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.microscope.healthcare.nikon.com/products/software/nis-elements">https://www.microscope.healthcare.nikon.com/products/software/nis-elements</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cryoSPARC v.3.3.2</td><td align="left" valign="bottom">Structura Biotechnology</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cryosparc.com/">https://cryosparc.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sf9 insect cells for expression</td><td align="left" valign="bottom">Expression Systems</td><td align="char" char="ndash" valign="bottom">94–001S</td><td align="left" valign="bottom">Sf9 cell line used for protein expression (Methods)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Insect cell media</td><td align="left" valign="bottom">Expression Systems</td><td align="char" char="hyphen" valign="bottom">96-001-01</td><td align="left" valign="bottom">Sf9 cell media (Methods)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Hellmanex III cleaning solution</td><td align="left" valign="bottom">Fisher</td><td align="char" char="hyphen" valign="bottom">14-385-864</td><td align="left" valign="bottom">Cleaning solution for TIRF experiments (PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/36842083">36842083</ext-link>)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Six-well sticky-side chamber</td><td align="left" valign="bottom">IBIDI</td><td align="char" char="." valign="bottom">80608</td><td align="left" valign="bottom">Side chamber used for TIRF experiments (Methods)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">C-Flat 2/2T grids</td><td align="left" valign="bottom">Electron Microscopy Sciences</td><td align="left" valign="bottom">CFT-223C</td><td align="left" valign="bottom">Grids used for EM studies (Methods)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">PDB coordinate file for p110γ-NB7 structure</td><td align="left" valign="bottom">PDB</td><td align="char" char="." valign="bottom">8DP0</td><td align="left" valign="bottom">PDB to use for p110-NB7 structure</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">EM density file for p110γ-NB7 complex</td><td align="left" valign="bottom">EMD</td><td align="left" valign="bottom">EMD-27627</td><td align="left" valign="bottom">EM density file to use for p110-NB7</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HDX-MS and phosphorylation proteomics data</td><td align="left" valign="bottom">PRIDE</td><td align="left" valign="bottom">PXD040765</td><td align="left" valign="bottom">Database and number where HDX data was uploaded</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88058.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Andreotti</surname><given-names>Amy H</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Iowa State University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd><kwd>Important</kwd></kwd-group></front-stub><body><p>This study presents <bold>fundamental</bold> new insight into the regulatory apparatus of PI3Kgamma; an <bold>important</bold> kinase in signaling pathways that control the immune response and cancer. A suite of biophysical and biochemical approaches provide <bold>convincing</bold> evidence for new sites of allosteric control over enzyme activity. The rigorous findings provide structure and dynamic information that may be exploited in efforts to control PI3Kgamma activity in a therapeutic setting.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88058.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors examine signaling factors that differentiate parallel routes to activating phosphoinositide 3-kinase gamma (PI3Kγ). Dissecting the convergent pathways that control PI3Kγ activity is critical because PI3Kγ is a therapeutic target for treating inflammatory disease and cancer. Here, the authors employ a multipronged approach to reveal new aspects for how p84 and p101 pair with p110γ to activate the PI3Kγ heterodimer. The key instigator to this study is a previously reported inhibitory Nanobody, NB7. The hypothesized mechanism for NB7 allosteric inhibition of p84- p110γ was previously proposed to involve blockage of the Ras-binding domain. The authors revise the allosteric inhibition model based on meticulous profiling of various PI3Kγ complex interactions with NB7. In parallel, a cryo-EM-derived model of NB7 bound to the p110γ subunit convincingly reveals a Nanobody interaction pocket involving the helical domain and regulatory motifs of the kinase domain. This revelation shifts the focus to the helical domain, a known target of PKC phosphorylation. While the connections between NB7 interactions and the effects of PKC phosphorylation are sometimes tenuous, it could be argued that the Nanobody served as a tool to reveal the importance of the helical domain to p110γ regulation.</p><p>The sites of PKC-mediated p110γ helical domain phosphorylation were unexpectedly inaccessible in the available structural models. Nevertheless, mass spectrometry (MS)-based phosphorylation profiling indicates that PKC can phosphorylate the helical domain of p110γ and p84/p110γ (but not p101/p110γ) in vitro. The authors hypothesize that helical domain dynamics dictate susceptibility to PKC phosphorylation. To explore this notion, carefully executed, rigorous H/D exchange MS (HDX-MS) experiments were performed comparing phosphorylated vs. unphosphorylated p110γ. Notably, this design reveals more about the consequences of p110γ phosphorylation, rather than the mechanisms of p84/p101 promoting/resisting phosphorylation. Nevertheless, HDX-MS is very well suited to exploring secondary structure dynamics, and helical domain phosphorylation strikingly increases dynamics consistent with increased regional accessibility. The increased dynamics also nicely map to the pocket enveloped by the inhibitory NB7 Nanobody.</p><p>Ultimately, this study reveals an unexpected p110γ pocket that allows an engineered Nanobody to allosterically inhibit PI3Kγ complexes. The cryo-EM characterization of the interaction inspired an HDX-MS investigation of known sites of phosphorylation in the region. These insights could be linked to differences/convergences of p84 and p101 complex formation and activation of PI3Kγ, and future work may clarify these mechanisms further. The data presented herein will also be useful for broadening the target surface for future therapeutic developments. New allosteric connections between effector binding sites and post-translational modifications are always welcome.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88058.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Harris et al. have described the cryo-EM structure of PI3K p110gamma in a complex with a nanobody that inhibits the enzyme. This provided the first structure of full-length of PI3Kgamma in the absence of a regulatory subunit. This nanobody is a potent allosteric inhibitor of the enzyme, and might provide a starting point for developing allosteric, isotype-specific inhibitors of the enzyme. One distinct effect of the nanobody is to greatly decrease the dynamics of the enzyme as shown by HDX-MS, which is consistent with a growing body of observations suggesting that for the whole PI3K superfamily, enzyme activators increase enzyme dynamics.</p><p>The most remarkable outcome of the study is that upon observing the site of nanobody binding, the authors searched the literature and found that there was a previous report of a PKCbeta phosphorylation of PI3Kgamma in the helical domain that is near the nanobody binding site. This led the authors to re-examine the consequence of the phosphorylation armed with better structural models and the tools to study the effects of this phosphorylation on enzyme dynamics. They found that the site of phosphorylation is buried in the helical domain, suggesting that a large conformational change would have to take place to enable the phosphorylation. HDX-MS showed that phosphorylation at three sites clustered in the helical domain generate a distinctly different conformation with rapid deuterium exchange. This suggests that the phosphorylation locks the enzyme in a more dynamic state. Their enzyme kinetics show that the phosphorylated, dynamic enzyme is activated.</p><p>While this phosphorylation was reported before, the authors have provided a mechanism for why this activates the enzyme, and they have shown why binders that stabilise the helical domain (such as binding to the p101 regulatory subunit and the nanobody) prevent the phosphorylation. It is this insight into the dynamics of the PI3Kgamma that will likely be the long-lasting influence of the work.</p><p>The paper is well written and the methods are clear.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88058.3.sa3</article-id><title-group><article-title>Author Response:</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Harris</surname><given-names>Noah J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Jenkins</surname><given-names>Meredith L</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Nam</surname><given-names>Sung-Eun</given-names></name><role specific-use="author">Author</role><aff><institution>University of British Columbia</institution><addr-line><named-content content-type="city">Vancouver</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Rathinaswamy</surname><given-names>Manoj K</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Parson</surname><given-names>Matthew AH</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Ranga-Prasad</surname><given-names>Harish</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Dalwadi</surname><given-names>Udit</given-names></name><role specific-use="author">Author</role><aff><institution>University of British Columbia</institution><addr-line><named-content content-type="city">Vancouver</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Moeller</surname><given-names>Brandon E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Sheeky</surname><given-names>Eleanor</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Scott D</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oregon</institution><addr-line><named-content content-type="city">Eugene</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yip</surname><given-names>Calvin K</given-names></name><role specific-use="author">Author</role><aff><institution>The University of British Columbia</institution><addr-line><named-content content-type="city">Vancouver</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Burke</surname><given-names>John E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Victoria</institution><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Canada</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors' response to the original reviews.</p><p>We appreciate the in depth review of our manuscript, and the excellent suggestions from the two reviewers. We have addressed all concerns as described in the point by point response below. We have also added all of these changes to a revised version posted to biorxiv on May 23rd 2023 (BIORXIV/2023/536585).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>It is sometimes difficult to connect the rationalizations behind the transitions between NB7 binding interaction, the compare/contrast of p84 and p101 effectors, and the synergy with phosphorylation. More explanation of the rationalizations behind these transitions in the Results would be helpful.</p></disp-quote><p>We agree that the manuscript would benefit from better transitions between the sections. We have added a new paragraph in the final section describing the nanobody structure before the helical domain phosphorylation that fully describes the rationale for how both inform on the critical role of helical domain dynamics in kinase activity. This paragraph is shown below.</p><p>_‘The interface of NB7 with p110_g _is distant from both the putative membrane binding surface, as well as the catalytic machinery of the kinase domain. To further understand how this nanobody could so potently inhibit PI3K activity we examined any other potential modulators of PI3K activity localised in this region. There are two regulatory phosphorylation sites in the helical (Walser et al., 2013) and kinase domain (Perino et al., 2011) localised at the NB7 interface. This is intriguing as helical domain phosphorylation is activating, and kinase domain phosphorylation is inhibitory. This suggested a critical role in the regulation of p110_g <italic>is the dynamics of this kinase-helical interface. To fully define the role of NB7 in altering the dynamics of the helical domain we needed to study other modulators of helical domain dynamics.’</italic></p><disp-quote content-type="editor-comment"><p>The Methods section would benefit from careful copy editing for clarity and consistency.</p></disp-quote><p>We have gone through the methods section and edited for clarity and consistency throughout.</p><disp-quote content-type="editor-comment"><p>There's a minor ambiguity throughout when referring to the phosphorylation of S594/S595. Although close inspection makes it clear that this refers to the monophosphorylation of either site S594 or S595, there are several references to &quot;S594/S595&quot; that could be interpreted as phosphorylation of both residues.</p></disp-quote><p>We agree that this was ambiguous in the original text. We have added an explicit statement describing this as a single phosphorylation event.</p><p><italic>‘The modification at this site results in a single phosphorylation event , but due to CID MS/MS fragmentation we cannot determine which site is modified, and will be described as S594/S595 throughout the manuscript.’</italic></p><disp-quote content-type="editor-comment"><p>In Figure 2B, the authors show the cryo-EM density map and the structural model based on this map. It would be helpful to also include an image of the structural model fit in the density map to allow readers to evaluate the quality of the map and model. The 2F panel provides an important view of this fit, but CD3 models are difficult to discern.</p></disp-quote><p>We agree that this would help interpret model quality. We have added a new supplemental figure showing the fit of both p110 and NB7 into this Cryo EM density (see new Fig S2).</p><disp-quote content-type="editor-comment"><p>Paragraph starting at line 258: The shift to monitoring ATPase activity is confusing here. ATPase activity indicates production of ADP + phosphate (rather than ADP + PIP3). However, an explanation is provided that states that measuring ADP production serves as a surrogate for measuring PIP3 production. The apparent absence of membrane PIP2 substrate in Figure 4E (left) suggests that there is a true ATPase background activity in this kinase. If so, does the increase in ADP production in Fig. 4E reflect the inclusion of PIP2 substrate, increased background ATPase activity, or both?</p></disp-quote><p>We agree that this was worded confusingly in the original version. We have now clarified exactly what we are observing in these ATPase assays. The new paragraph is appended below</p><p><italic>‘To further explore the potential role of phosphorylation in mediating p110g activity, we examined the kinase activity of p110g under two conditions: basal ATP turnover, and with PIP2 containing lipid membranes. The experiments in the absence of PIP2 measure turnover of ATP into ADP and phosphate, and is a readout of basal catalytic competency. Experiments with PIP2, measured ATP consumed in the generation of PIP3, as well as in non-productive ATP turnover. The p110g enzyme in the absence of stimulators is very weakly active towards PIP2 substrate with only ~2 fold increased ATP turnover compared to in the absence of membranes. This is consistent with very weak membrane recruitment of p110g complexes in the absence of lipid activators (Rathinaswamy et al., 2023). PKCb-mediated phosphorylation enhanced the ATPase activity of p110g ~2-fold in both the absence and presence of membranes (Fig. 4E). This suggests that the effect of phosphorylation is to change the intrinsic catalytic efficiency of phosphorylated p110g, with limited effect on membrane binding.’</italic></p><disp-quote content-type="editor-comment"><p>In the section &quot;Nanobody blocks p110gamma phosphorylation,&quot; it's not entirely convincing that &quot;the presence of NB7 showed even lower phosphorylation than p110gamma-p101.&quot; This does not seem to be subject to a significance test in Figure 5A/B. The follow-up point about &quot;complete abrogation of phosphorylation,&quot; however, is readily apparent.</p></disp-quote><p>We agree that we could have been more precise with our language, as this is not a complete block of phosphorylation, it is merely a significant decrease in phosphorylation. We have removed the comparison to p110-p101, and also removed the statement about complete abrogation of phosphorylation. This is now reworded to</p><p><italic>‘The presence of NB7 showed a significant decrease in p110g phosphorylation at both sites (Fig. 5A-B).’</italic></p><disp-quote content-type="editor-comment"><p>Figure 1: Legend needs to include more detail to define the data. (1A) Representations of variance need to be clarified (e.g., replicates, error bar meaning). Consider &quot;Normalized lipid kinase activity&quot; as a y-axis label and expand on the activity measurement and normalization in the legend. (1B) How was error calculated? (1C) Mislabeled as 1B? Also, consider clarifying the first title highlighting the comparison to class IA PI3Ks. (1D) Typo: &quot;Y647-p84/p110gamma.&quot; Also, would it not be more accurate to say &quot;effect of nanobody NB7 on PI3K displacement...&quot; for this experiment?</p></disp-quote><p>We apologise for these oversights. See details on what has been changed in Fig 1A, 1B, 1C, and 1D.</p><p>For Fig 1A we now show the data where each replicate is indicated in the graph in the absence of error bars, and have also more clearly expanded on this activity measurement in the figure legend and also stated the replicate number.</p><p>For Fig 1B we now clearly state how the error was generated.</p><p>For Fig 1C we have fixed the typo</p><p>For Fig 1D, we have fixed this typo and also changed the sub-heading as suggested.</p><p>New figure legend is below as well</p><p><bold><italic>Figure 1. The inhibitory nanobody NB7 binds tightly to all p110γ complexes and inhibits kinase activity, but does not prevent membrane binding</italic></bold></p><p><bold><italic>A.</italic></bold><italic>Cartoon schematic depicting nanobody inhibition of activation by lipidated Gβγ (1.5 µM final concentration). Lipid kinase assays show a potent inhibition of lipid kinase activity with increasing concentrations of NB7 (3-3000 nM) for the different complexes. Experiments are carried out in triplicate (n=3) with each replicate shown. The y-axis shows lipid kinase activity normalised for each complex activated by Gβγ in the absence of nanobody. Concentrations of each protein were selected to give a lipid kinase value in the detectable range of the ATPase transcreener assay. The protein concentration of p110γ (300 nM), p110γ-p84 (330 nM) and p110γ-p101 (12 nM) was different due to intrinsic differences of each complex to be activated by lipidated Gβγ, and is likely mainly dependent for the difference seen in NB7 response.</italic></p><p><bold><italic>B</italic></bold><italic>. Association and dissociation curves for the dose response of His-NB7 binding to p110γ, p110γ-p84 and p110γ-p101 (50 – 1.9 nM) is shown. A cartoon schematic of BLI analysis of the binding of immobilized His-NB7 to p110γ is shown on the left. Dissociation constants (KD) were calculated based on a global fit to a 1:1 model for the top three concentrations and averaged with error shown. Error was calculated from the association and dissociation value (n=3) with standard deviation shown. Full details are present in the source data.</italic></p><p><bold><italic>C</italic></bold><italic>. Association and dissociation curves for His-NB7 binding to p110γ, p110a-p85a, p110b-p85b, and p110d-p85b. Experiments were performed in duplicate with a final concentration of 50 nM of each class I PI3K complex.</italic></p><p><bold><italic>D</italic></bold><italic>. Effect of NB7 on PI3K recruitment to supported lipid bilayers containing H-Ras(GTP) and farnesyl-Gbg as measured by Total Internal Reflection Fluorescence Microscopy (TIRF-M). DY647-p84/p110g displays rapid equilibration kinetics and is insensitive to the addition of 500 nM nanobody (black arrow, 250 sec) on supported lipid bilayers containing H-Ras(GTP) and farnesyl-Gbg.</italic></p><p><bold><italic>E</italic></bold><italic>. Kinetics of 50 nM DY647-p84/p110g membrane recruitment appears indistinguishable in the absence and presence of nanobody. Prior to sample injection, DY647-p84/p110g was incubated for 10 minutes with 500 nM nanobody.</italic></p><p><bold><italic>F</italic></bold><italic>. Representative TIRF-M images showing the localization of 50 nM DY647-p84/p110g visualized in the absence or presence of 500 nM nanobody (+NB7). Membrane composition for panels C-E: 93% DOPC, 5% DOPS, 2% MCC-PE, Ras(GTP) covalently attached to MCC-PE, and 200 nM farnesyl-Gbg.</italic></p><disp-quote content-type="editor-comment"><p>Figure 2: (1A) For consistency with the rest of the paper, p110g can be updated with the Greek character. (1B) This may have been intentional to attract attention to subdomains interacting with NB7, but &quot;colored according to the schematic&quot; omits the purple RBD. (2F) the figure legend should specify whether p110gamma surfaces depicted are the cryo-EM density or a surface rendition of the structural model.</p></disp-quote><p>We agree and have fixed the p110 typo, and have also colored the schematic the same as shown in the cartoon model.</p><p>The data shown in Fig 1B is indeed the Cryo EM density and this is now clearly indicated in the legend.</p><disp-quote content-type="editor-comment"><p>Figure 3: (3B) Specifying the [M+H] as [M+2H]2+ and [M+4H]4+ would help the reader understand the delta mass for monophosphorylation here. Given the broad readership of this journal, it would be useful to define 't' and 'e' as 'theoretical' and 'experimental' in the legend. It may also help to be explicit about the meaning of the red spectra and residues in the legend. (3C-E) autocorrect typo for &quot;(C)&quot; and an opportunity to update &quot;b&quot; for Greek character beta.</p></disp-quote><p>We agree that clearly defining the charge state of each spectra will make it more obvious that we are dealing with a mono-phosphorylation and have made this change as suggested in the figure. We have also clearly define m/z t and m/z e in the figure legend, as well as the black and red lines, and characters. Finally we have added PKCb for all descriptions of PKC treatment in the figure, and fixed the incorrect PKC’b’ in the legend.</p><disp-quote content-type="editor-comment"><p>Figure 4: (4C) Given the common use of &quot;ND&quot; for other terms, it would be useful to spell out &quot;no deuterium&quot; or &quot;undeuterated.&quot; (4E) the parenthetical &quot;(concentration, 12nM to 1000nM)&quot; could be clarified. How are the (presumably p100gamma) concentration ranges reflected in the three plotted data points per treatment? See also Figure 5E.</p></disp-quote><p>We agree and have redefined ND as undeuterated. We apologise for the typo in the figure legend, as the concentrations of p110 gamma were the same for both phosphorylated and non-phosphorylated, with this being a typo (all concentrations of enzyme were 1000 nM). This has been changed here and in Fig 5E.</p><disp-quote content-type="editor-comment"><p>Figure 5: (5A/B) Some clarification that we're looking at extracted ion chromatograms would be very useful in this figure legend. On a related note, the experimental details on the LC-MS methodology for this data appear to be split between two sections of the Methods: the &quot;Phosphorylation analysis&quot; paragraph (line 526) and the HDX-MS section. Some more explicit cross-referencing would clarify this experiment. (5E) Clarify inclusion of PIP2 membranes here.</p></disp-quote><p>We have clearly described that we are looking at extracted ion chromatograms in both panel A and B. We also have normalized the experimental methods in the LC-MS as these used exactly the same procedure. Finally, we now clearly describe the assays shown in Fig 5E were performed in the absence of PIP2 membranes.</p><disp-quote content-type="editor-comment"><p>Miscellaneous typos:</p><p>Line 205: reference omitted for &quot;Previous study..&quot;</p></disp-quote><p>We have added this reference</p><disp-quote content-type="editor-comment"><p>Line 196: &quot;unambiguous&quot;</p></disp-quote><p>Fixed to unambiguously</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The only mistake I spotted was that on line 729 there is a reference to Fig 3C that should actually be Fig. 4C</p></disp-quote><p>We have changed this to the correct Fig 4C.</p></body></sub-article></article>